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Preface 
This thesis is a compilation of published and unpublished work investing the 
underlying properties of the bifunctional natural product FK506 and how it may be 
leveraged in the design of effective therapeutics. In Chapter 1, I introduce the 
super family of Peptidyl-prolyl isomerases, their role in disease, and the 
mechanism of the bifunctional natural products FK506, rapamycin and 
cyclosporine. A portion of this Chapter was published as: “Dunyak, B.M. & 
Gestwicki, J.E. Peptidyl-Proline Isomerases (PPIases): Targets for Natural 
Products and Natural Product-Inspired Compounds. J. Med. Chem. In press. 
(2016).” In Chapter 2, I synthesized bifunctional molecules related to FK506 that 
simultaneously bind FKBP12 and HIV protease and characterized them using 
biochemical assays. In Chapter 3, I explored the cyto-selective properties of our 
bifunctional molecules using a cell-based GFP reporter and live virus HIV infectivity 
assays. These results suggested key design principles underlying cyto-selective 
bifunctional molecules and are published as “Dunyak, B.M., Nakamura, R.L., 
Frankel, A.D. & Gestwicki, J.E. Selective Targeting of Cells via Bispecific 
Molecules That Exploit Coexpression of Two Intracellular Proteins. ACS Chem Biol 
10, 2441-7 (2015).” In Chapter 4, FK506 was semisynthetically modified to furnish 
an amine substituted derivative, FK-NH2. This molecule was modified to develop 
potential Pin1 inhibitors, one of which had modest affinity for Pin1. This work is 
vi 
 
currently ongoing. In Chapter 5, I summarize the work herein and highlight future 
directions. 
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Abstract 
Peptidyl-prolyl isomerases (PPIases) are a ubiquitously expressed super family of 
proteins that catalyze the cis/trans isomerization of prolyl bonds. Proline 
conformation acts as a regulatory switch during folding, activation and/or 
degradation of “clients” that include proteins with roles in cancer and 
neurodegeneration. PPIase inhibitors, therefore, could be important therapeutics. 
However, the active site of PPIases is shallow and well conserved between 
members, challenging selective inhibitor design. Despite this, macrocyclic natural 
products, including FK506, rapamycin and cyclosporin, bind PPIases with 
nanomolar or better affinity. These natural products possess an unusual 
“bifunctional” binding mode and bind two separate proteins simultaneously, which 
is critical for their activity. They exhibit remarkable pharmacological properties, 
including oral bioavailability, and rapidly accumulate in cells with widespread tissue 
distribution.  
 
Inspired by this mechanism, I synthesized a library of bifunctional molecules that 
bind both FKBP12 and HIV protease. Like FK506, we envisioned a model where 
coincident, high-level expression of both targets - as in HIV-infected lymphocytes 
with high levels of FKBP12 and HIV protease - would drive cyto-selective 
sequestration. The library possessed varying affinities for each target, retained 
xxiv 
 
passive membrane permeability, and had cellular activity. Molecules highly potent 
for FKBP12 and HIV protease were selectively taken up into relevant cell 
populations. Treatment with FKBP12 inhibitors limited partitioning of the 
molecules, while FKBP12 overexpression enhanced it. This suggests that avidity 
effects drive selective accumulation of bifunctional molecules in cells expressing 
high levels of both protein partners. 
 
We next focused on Pin1, a unique PPIase that binds prolines directly following 
phosphoserine/threonine residues. The requirement for an electronegative group 
in the Pin1 active site renders many inhibitors inactive from poor permeability. We 
hypothesized that the excellent pharmacological properties of FK506 might make 
it a suitable scaffold for engineering Pin1 inhibitors. However, FK506 has little 
affinity for Pin1, because it lacks the key electronegative region essential for Pin1 
binding. To overcome this, we designed a novel semisynthetic strategy to modify 
FK506 at a position to improve affinity for Pin1. Installing a sulfamic acid 
significantly improved the affinity for Pin1 (>100-fold) in vitro. This strategy is 
designed to yield high-affinity membrane-permeable inhibitors of Pin1. 
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Chapter 1  
The Superfamily of Peptidyl-Prolyl Isomerases: Targets of 
Macrocyclic Natural Products  
 
1.1 Abstract 
Peptidyl-prolyl isomerases (PPIases)  are a chaperone superfamily comprising the 
FK506-binding proteins (FKBPs), cyclophilins and parvulins. PPIases catalyze the 
cis/trans isomerization of peptidyl-prolyl bonds, acting as a regulatory switch during 
folding, activation and/or degradation of many proteins. These “clients” include 
proteins with key roles in cancer, neurodegeneration and psychiatric disorders, 
suggesting that PPIase inhibitors could be important therapeutics. However, the 
active site of PPIases is well conserved between members, making selective 
inhibitor design challenging. Further, the active site is shallow and solvent-
exposed. Despite these hurdles, macrocyclic natural products, including FK506, 
rapamycin and cyclosporin, bind PPIases with nanomolar or better affinity. 
Attempts to derive synthetic inhibitors de novo have been somewhat less 
successful, often showcasing the “undruggable” features of PPIases. Interestingly, 
the most potent synthetic molecules tend to integrate features of the natural 
products, including macrocyclization or proline mimicry strategies. Lastly, the 
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aforementioned macrocyclic natural products possess an unusual binding mode; 
they are naturally bifunctional and able to bind two separate protein targets 
simultaneously. For example, FK506 binds the FKBPs with one chemical face and 
calcineurin with another, non-overlapping motif to facilitate the formation of a stable 
ternary complex. In each case, binding two proteins at the same time is critical to 
the natural product’s activity. 
 
1.2 PPIases are a Superfamily of Molecular Chaperones 
Peptidyl-prolyl isomerases (PPIases) are a superfamily of molecular chaperones 
that play widespread roles in protein folding and regulation through isomerization 
of proline residues.[1, 2] Unlike other chaperones,[3] PPIases do not utilize co-
factors, such as ATP, to drive their activity; rather, they bind their “clients” using a 
shallow and promiscuous interface that is thought to favor proline isomerization 
through conformational selection. As discussed below, this deceptively simple 
mechanism is critical to the folding and function of numerous “clients”. Indeed, 
genetic studies have shown that PPIases are essential to the function/folding of 
proteins important in cancer, neurodegenerative disorders, viral infection and 
psychiatric disorders.[4-7]  
 
Despite the lack of deep, “druggable”[8] sites in the PPIases, nature has repeatedly 
found ways of creating potent PPIase inhibitors, as exemplified by the macrocycles 
FK506, rapamycin and cyclosporin. These natural products have been key probes 
for understanding PPIase function and were even used to identify members of the 
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PPIase family.[9] Here, we briefly discuss the structure and function of PPIases, 
their roles in disease, and our understanding of how natural products have 
informed recent developments in the search for selective, potent PPIase inhibitors.  
 
1.3 Proline Isomerization in Protein Folding and Function 
Peptide bonds in proteins are dominated by the trans conformation due to the 
steric clashes that occur at the alpha carbon in the cis orientation. However, proline 
is different (Figure 1.1A). The cyclized side chain of proline samples both the cis 
and trans conformations, typically in a ratio of ~20% cis to ~80% trans. 
Spontaneous isomerization of the Xaa-Pro bond is slow (on the timescale of 
 
Figure 1.1) Proline can sample discrete cis and trans conformations, which isomerize 
on the timescale of milliseconds-to-seconds. A) Depiction of the proline conformations, 
with the backbone cis and trans orientations highlighted as an orange dotted line. B) 
Average timescales of processes important in protein folding, illustrating that 
uncatalyzed proline isomerization can often be a rate-limiting step. 
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milliseconds to seconds), creating a particular challenge to protein folding because 
the majority of folding events occur on the microsecond-to-millisecond 
timescale.[10] Thus, proline isomerization can be rate limiting, requiring PPIases 
to alleviate the bottleneck (Figure 1.1B).[11, 12] Beyond folding, this special 
feature of proline has been exploited as a regulatory switch in signal transduction. 
For example, oncogenic p53 is activated after binding of the PPIase Pin1, 
enhancing malignancy in transformed cells.[13, 14] 
 
1.4 FKBPs, Cyclophilins and Parvulins 
1.4.1 Architecture of the PPIase domain 
PPIases are a superfamily consisting of the immunophilins and parvulins. In turn, 
the immunophilin family is further subdivided into the FKBPs and cyclophilins. In 
humans, there are 18 FKBPs, 24 cyclophilins and 3 parvulins.[15, 16] Each of the 
PPIases contains at least one PPIase domain. This domain is composed of 
antiparallel β-strangds that position a short α-helix. A shallow groove between the 
α-helix and β-sheet forms a small, solvent-exposed active site that binds to the 
 
Figure 1.2) Ribbon diagrams of the global folds of the representative PPIase domains 
of FKBP12, CypA and Pin1.The client binding pockets are depicted as a mesh cavity 
(produced in PyMol). (PDB: 1FKB, 1BCK, 1PIN, respectively) 
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target proline (Figure 1.2). Generally, a planar aromatic residue on the floor of the 
pocket mediates a critical hydrophobic interaction with proline. In the prototypical 
PPIases FKBP12, cyclophilin A (CypA)  and Pin1, this interaction is facilitated by 
Trp-59, Phe-113 and Phe-134, respectively. The stabilizing role of Trp-59 has been 
extensively studied by NMR.[17] The catalytic mechanism of isomerization is not 
entirely clear, with previous studies suggesting that the PPIases may force a 
twisted-amide transition state.[18, 19] Stabilization is conferred by hydrophobic 
residues within the pocket alongside crucial hydrogen bonds formed with the 
proline backbone and adjacent residues (Figure 1.3A). In CypA, this interaction is 
carried out by Arg-55, which forms hydrogen bonds with the proline carbonyl 
oxygen in the trans state and proline amide nitrogen in the cis state.[20] These 
interactions have been studied by multi-temperature crystallography,[21] revealing 
the dynamical nature of the active site. The roles of the active site residues in 
FKBP12 are less clear, although mutagenesis experiments have implicated Asp-
 
Figure 1.3) PPIases have a shallow, broad active site. A) Surface representation of the 
representative PPIase domains from FKBP12, CypA and Pin1. The active site region is 
shaded in gray, with critical residues for catalysis shown. B) High-affinity ligands for each 
PPIase are bound to the active site and engage the proline-binding pocket. Surface 
charges depicted (blue is positive, red is negative). 
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37 and His-87 in forming a hydrogen bond network between the pocket and bound 
client.[22] In Pin1, there is an active site Cys-113 that was initially thought to 
operate via covalent nucleophilic attack on the client. However, follow-up studies 
demonstrated that the cysteine could be mutated to serine (C113S) or aspartate 
(C113D) without loss of function, suggesting that hydrogen bonding is more 
important.[23] This model is further supported by the observation that Cys-113 is 
replaced by Asp-74 in the related family member, Parvulin-14.[24] Beyond this 
residue, a substantial hydrogen-bonding network involving His-59 and His-157, 
helps stabilize interactions with clients in Pin1.[24] Thus, all of the PPIases feature 
a key, floor residue that is supported by hydrophobic interactions and a hydrogen-
bonding network surrounding the active site, although the exact identity of the 
residues often varies substantially. The best inhibitors of the PPIase access all of 
these regions (Figure 1.3B), which is a challenge given the extended dimensions 
of the pocket. 
 
1.4.2 FKBPs 
The FKBPs are a sub-family of 18 proteins and they are named for their apparent 
molecular mass. The 12 kDa family member, FKBP12 (gene FKBP1A), is 
composed of just a PPIase domain. It is widely expressed, but especially abundant 
in skeletal and cardiac muscle, the central nervous system, peripheral nerves and 
blood cells.[25, 26] The cellular roles of FKBP12 are not entirely clear despite its 
abundance; knockout mice exhibit a cardiac muscle phenotype and behavioral 
changes associated with several neurological disorders.[27, 28] FKBP12 likely 
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acts as a chaperone in protein folding and the knockout phenotypes suggest that 
its activity may be redundant with other PPIases in many instances. The other 
members of the FKBP family have, in addition to at least one PPIase domain, other 
modules. These other domains provide additional functions and often serve as 
scaffolds between the PPIase clients and other cellular pathways. For example, 
FKBP51 (gene FKBP5) and FKBP52 (gene FKBP4) share 70% sequence identify 
and possess three domains, two PPIase domains (FK1 and FK2) and a C-terminal 
tetratricopeptide repeat (TPR)  domain.[6] The FK1 domain has PPIase activity 
and it binds both rapamycin and FK506 (FKBP51: KDRapa ≈ 3.7 nM, KDFK506 ≈ 104 
nM; FKBP52: KDRapa ≈ 4.2 nM, KDFK506 ≈ 23 nM)[29] with similar affinity as FKBP12. 
The function of the FK2 domain is still largely unknown. FK2 does not bind FK506 
or rapamycin and it does not have measurable isomerase activity in vitro. Through 
their TPR domains, FKBP51 and FKBP52 interact with the unstructured C-terminal 
tail of the chaperone, heat shock protein 90 (Hsp90), which links them to steroid 
hormone receptor maturation.[30-32] Interestingly, despite their high homology to 
each other, FKBP52 positively regulates the stability of androgen, glucocorticoid 
and progesterone receptors while FKBP51 acts as a negative regulator. Through 
this activity, FKBP52 has been implicated as a target in hormone-driven tumors, 
such as prostate cancer, colorectal adenocarcinomas, breast cancer and 
myelomas.[6] The functional differences between FKBP51 and FKBP52 have 
been isolated to dynamical changes in FK1.[33] In addition to steroid hormone 
signaling, the complex between Hsp90 and these FKBPs has also been shown to 
interact with intrinsically disordered proteins, such as tau.[34] In Alzheimer’s 
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disease models, FKBP51-Hsp90 is associated with tau retention, while FKBP52-
Hsp90 is linked to tau degradation through the proteasome.[35, 36] However, 
FKBP52 is also associated with promoting tau aggregation[37, 38] and inhibitors 
have shown promise in tauopathy models.[39] FKBP38 (gene FKBP8) has a single 
PPIase domain, which is normally inactive. However, this family member also has 
a TPR domain and a putative calmodulin-binding motif. Increases in Ca2+ trigger a 
conformational change that recruits calmodulin and activates the PPIase domain. 
In response to intracellular Ca2+, activated FKBP38 then becomes competent for 
binding to the anti-apoptotic protein, Bcl-2. The exact role of FKBP38 in regulation 
of Bcl-2 activity remains enigmatic, with conflicting results suggesting that FKBP38 
may either promote or inhibit apoptosis.[40]  
 
1.4.3 Cyclophilins 
Similar to the FKBPs, cyclophilins contain at least one PPIase domain and are 
widely distributed across tissue types.[41] The most abundant cyclophilin, 
cyclophilin A (CypA, gene PPIA), was named after the discovery of its ability to 
potently bind cyclosporin A (KD ≈ 6 nM).[42, 43] CypD, a mitochondrial cyclophilin, 
has been implicated in mitochondrial permeability transition (MPT)  pore opening, 
allowing for the release of pro-apoptotic factors into the cytosol.[44] It is thought 
that CypD binds the adenine nucleotide translocase (ANT)  machinery directly. 
Under stress conditions, this facilitates a Ca2+-mediated conformational change in 
ANT, altering the role of ANT from a nucleotide transporter to an open pore.[45] 
Analogous to FKBP51/52, Cyp40 contains a TPR domain and interfaces with 
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Hsp90, facilitating complex formation with the estrogen receptor to modulate 
steroid hormone receptor maturation and trafficking.[46] 
 
1.4.4 Parvulins 
Lastly, the parvulins make up the smallest family of PPIases, consisting of: 
peptidyl-prolyl cis/trans isomerase NIMA interacting protein 1 (Pin1), Parvulin-14 
(Par14)  and Parvulin-17 (Par17). The parvulins were originally discovered as a 
novel PPIase family in Escherichia coli.[47] Human parvulins can be subdivided 
into two groups by substrate specificity. Par14 and Par17, products of alternative 
transcription initiation of the parvulin gene,[48] are similar to the prokaryotic 
parvulins and exhibit the conserved isomerase and chaperoning activity 
characteristic to most PPIases. The exact cellular functions of Par14 and Par17 
are still cryptic. Par14 has been found both in the cytosol and nucleus, reportedly 
binding DNA[49]  and assisting in rRNA processing for ribosome biogenesis.[50] 
Less is known about Par17, although it has been shown to promote microtubule 
assembly[51] and it contains a mitochondrial targeting sequence, where it is 
implicated in DNA binding.[52] Pin1, the third member of the parvulin family, is 
unique among all PPIases because it only recognizes prolines that are adjacent to 
phosphorylated serine/threonine residues (i.e. the pS/T-P motif). Pin1 also has an 
N-terminal WW domain, which similarly binds to the pS/T-P motif and shares an 
overlapping client profile with the PPIase domain. The WW domain consists of two 
antiparallel β-strands that connect via a short linker to the PPIase domain, forming 
a hydrophobic patch that binds to substrate and coordinates the phosphorylated 
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serine/threonine via Arg-17. The WW domain does not possess intrinsic isomerase 
activity and it is not clear why it has an overlapping substrate preference. It is 
thought that the WW domain may help recruit Pin1 to relevant clients, but the hand-
off mechanism is unknown. What is clear is that Pin1 plays essential roles in cell 
division. For example, Pin1 regulates the activity of the phosphatase Cdc25, 
coordinating it with the cell cycle.[53] Pin1 also stabilizes the regulatory protein, 
cyclin D1, preventing its degradation and mediating its nuclear localization through 
the conformational switch of pThr286-Pro287.[54]  
 
1.5 Mechanisms of Bifunctional PPIase Ligands 
Two of the PPIases, FKBP12 and CypA, were discovered as the molecular targets 
of the natural products FK506, cyclosporin, and rapamycin, in a pre-genomic 
 
 
Figure 1.4) Bifunctional binding mode of the natural product rapamycin. A) Rapamycin 
forms a ternary complex with FKBP12 and the FRB) domain of mTOR).  B) The 
pipecolyl α-ketoamide of rapamycin anchors it into the proline-binding pocket, while 
leaving the triene exposed for interactions with mTor. C) Crystal structure of the 
FKBP12-rapamycin-mTOR ternary complex, showing the rapamycin-mediated 
organization of both protein partners. (PDB: 1FAP) 
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example of pharmacology leading to the discovery of a protein function.[42, 55-57] 
Subsequent work showed that FK506 forms a ternary complex between FKBP12 
(and other FKBPs)[58] and the phosphatase, calcineurin. Interestingly, cyclosporin 
and rapamycin have a conceptually similar way of binding their targets. 
Cyclosporin brings together CypA and calcineurin, while rapamycin facilitates the 
ternary complex between FKBPs and mTOR.[59] These molecules are able to bind 
both targets and are thus naturally “bifunctional”; rapamycin binds FKBPs with one 
chemical face and mTOR with another, non-overlapping motif (Figure 1.4A and 
1.4B) to facilitate the formation of a stable ternary complex (Figure 1.4C). In each 
case, binding two proteins at the same time is critical to the natural product’s 
immunsuppressive activity. For example, FK506 blocks the dephosphorylation and 
activation of the transcription factor NF-AT by using the steric bulk of FKBP12 to 
limit accessibility to the calcineurin active site.[60] It would be difficult for a small 
molecule to do this effectively on its own because of the shallow, open nature of 
the phosphatase pocket. Similarly, rapamycin blocks the G1 to S phase transition 
and prevents proliferation of activated T-cells by using FKBP12 to limit accessibility 
of substrates to mTOR.[61-63] Thus, the PPIase (i.e. FKBP12) isn’t necessarily 
the target that drives the biological affect, it is simply “along for the ride”.  
 
1.6 Chemically Induced Dimerization 
Over the last two decades, this mechanism has been exploited in dozens of 
chemical biology strategies. Synthetic, bifunctional molecules, which are based on 
the natural products, are used to control protein dimerization, stability, localization 
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and function.[64-69] Synthetic molecules based on FK506 have a long history of 
important uses in chemical biology and drug discovery.[64, 68, 70-74] The first 
example of a synthetic FK506 bifunctional derivative was used as a Chemical 
Inducer of Dimerization (CID), a generalizable tool for understanding the 
mechanism of receptor dimerization and signaling. Cellular expression of 
constructs consisting of a receptor of interest fused to FKBPs could be activated 
by the addition of a synthetic bifunctional FK506 ligand. Receptor activation via 
intracellular dimerization and oligomerization events were triggered by the addition 
of a cell-permeable “FK1012” ligand (Figure 1.5). In this way, signaling cascades 
could be initiated by addition of the exogenous ligand, allowing for temporal control 
of dimerization and subsequent signaling events. 
 
 
Figure 1.5) General schematic for Chemically Induced Dimerization (CID) to activate 
receptors. Receptor constructs fused to FKBPs (dark green) could be artificially 
dimerized by the addition of bifunctional FK506 ligands (inset and blue circles). This 
strategy can be used to study temporally controlled signaling events triggered by 
receptor oligomerization. 
13 
 
While FK506-based bifunctional ligands were effective as CIDs, their large 
molecular weight and overwhelming chemical complexity initially limited their 
usefulness. Further, these limitations presented challenges in the discovery of new 
ligands targeting the FKBPs as traditional chemical probes. Development of the 
early synthetic (e.g. non-natural product) FKBP12 inhibitors were designed to 
mimic the binding pose of FK506 (Figure 1.6A). The pipecolate core of FK506 is 
retained but the pyranose ring is replaced by a tert-pentyl substitution off the α-
ketoamide.[75, 76] Derivatization and optimization of the pipecolic ester to 
represent the cyclohexylethenyl group and stereospecific substitution at the 
carbinol center ultimately resulted in SLF[74], or Synthetic Ligand for FKBP. SLF 
was designed to retain most of the affinity of FK506 (Ki ≈ 20 nM), while also 
 
Figure 1.6) Synthetic Ligand for FKBP (SLF) binding to FKBP12 and representative 
SLF CIDs. A) SLF was designed to mimic the natural binding pose of FK506. B) 
Modification at the carboxylic acid allows for simple formation of bifunctional molecules 
for dimerization, recruitment of FKBPs to amyloids or delivery of FKBPs to E3 ubiquitin 
ligases for targeted degradation. (PDB: 4LAY, represented as an electrostatic surface) 
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including a pendant carboxylate that could be used to add additional functionalities 
that point away from the FKBP surface. Crystal structures confirmed that the 
compounds adopt a binding pose similar to FK506, largely driven by the pipecolyl 
ring interaction with Trp-59. The cyclohexylethenyl chain, replaced by the 
phenethyl fragments in the synthetic molecules, sits in the same hydrophobic 
groove, engaging in hydrophobic interactions with Ile-56 and Tyr-82. The most 
significant deviation from the FK506 pose occurs in the pyranose replacement, 
where a hydrogen bond with Asp-37 is lost. Nonetheless, native salt bridges are 
maintained and the tert-pentyl group makes productive Van der Waals contacts. 
Consistent with their design, these compounds lack immunosuppressant activity 
because they can no longer bind calcineurin. 
 
1.7  Heterodimeric Bi-specific Ligands  
In this way, SLF became a “go-to” molecule for creating CIDs (Figure 1.6B).[64, 
77] Typical CIDs were assembled by coupling SLF either to itself (AP1510)[74] or 
to other molecules to form heterodimeric ligands. Synthetic FK506 mimetics were 
likewise used for various CID applications. With similar potency as FK1012, 
AP1510 was able to dimerize FKBP12-Fas fusion proteins, activating Fas-
mediated apoptosis in HT1080 cells.[74] SLF tethered to the amyloid-binding 
ligand Congo Red (SLF-CR) was able to recruit FKBP12 chaperone proteins to 
sites of protein misfolding and aggregation, blocking Aβ fibril formation in vitro and 
in cell models of disease.[78] In an alternate approach, thalidomides could 
selectively target proteins for degradation via specific ligand conjugates that recruit 
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the cereblon E3 ubiquitin ligase; here, SLF conjugated thalidomide (dFKBP-1) 
selectively bound FKBP12 which was subsequently degraded.[79] Inspired by the 
natural mechanism of FK506, synthetic bifunctional molecules are promising 
candidates for future clinical development. 
 
In Chapters 2 and 3, I will explore a new aspect of bifunctional molecule design. 
Specifically, I synthesized bifunctional molecules that bind to FKBP12 on one end 
and HIV protease on the other. Using these molecules, I could selectively target 
cells that express both of the target proteins.  
 
1.8 Roles of PPIases in Disease 
More recently, the PPIases themselves have emerged as targets in their own right, 
and for a wide range of diseases.[80] The breadth of diseases linked to PPIases 
is staggering, likely because they have so many potential clients. For example, 
FKBP12 has been shown to modulate the activity of ryanodine receptor, inositol 
1,4,5-triphosphate receptor, TGF-β receptor 1 and activin type 1 receptor.[81, 82] 
Similarly, as mentioned above, FKBP51 and FKBP52, are critical for maturation 
and activity of the steroid hormone receptors, such as androgen receptor (AR)  and 
glucocorticoid receptor (GR) ,[83] FKBP38 is linked to the anti-apoptotic proteins 
Bcl-2/Bcl-xL matrix metalloproteinase 9 (MMP9),[40] FKBP25 regulates casein 
kinase II and nucleolin[84] and FKBP13 and FKBP65 control elements of the 
secretory pathway for protein trafficking and collagen biosynthesis.[85, 86] 
Similarly, the cyclophilins are involved in collagen remodeling,[87] function of the 
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steroid hormone receptors,[46, 88] and activation of numerous transcription 
factors.[41] The cyclophilins also play key roles in calcium signaling and 
homeostasis through activities on multiple clients.[45, 89] CypA binds the SH2  
domain of ITK  and regulates production of CD4+ Th2 cytokines.[90] Highly 
expressed in vascular smooth muscle cells, CypA may be excreted as an 
extracellular growth factor as a response to oxidative stress to mediate ERK1/2 
[91] and CD147[92] activation. In addition to these roles, cyclophilins have been 
shown to be critical host-factors that are co-opted by viruses.[93] For example, 
CypA regulates multiple steps in the human immunodeficiency virus type-1 (HIV-
1) life cycle and is repackaged into new virion particles during HIV replication and 
release. During Hepatitis C virus (HCV) infection, CypA and CypB  bind the 
regulator protein NS5A and RNA polymerase NS5B, which are critical for HCV 
replication. Other cyclophilins, such as CypD, have been implicated in Alzheimer’s 
disease through a direct interaction with Aβ.[94] The breadth of clients showcases 
how the PPIase active site must be shallow and malleable to accommodate a 
range of sequences and topologies around the central proline.  
 
After its discovery as a crucial regulator of cell cycle progression, Pin1 has since 
been shown to be involved in numerous phosphorylation-dependent regulatory 
mechanisms. Pin1 works in tandem with ‘proline-directed’ kinases and 
phosphatases, binding and isomerizing the peptide backbone of the pS/T-P motifs 
to alter the prolyl cis/trans conformation. This is especially important in the context 
of pS/T-P motifs, as they have been shown to isomerize 8-fold slower than their 
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non-phosphorylated counterparts.[95] Since proline isomerization already 
represents a significant bottleneck in protein folding and the conformational 
dynamics of proteins, phosphoprotein substrates of Pin1 require the specific 
isomerase activity of this chaperone to function (Figure 1.7). Pin1-mediated 
conformational changes act as a switch mechanism for activating transcription 
factors, facilitating dephosphorylation or degradation of clients, stabilizing protein-
protein interactions and targeting proteins for specific subcellular localization.[96] 
Accordingly, Pin1 has been linked to a particularly wide-spread set of client 
proteins, including transcription factors, oncogenes and neurodegenerative 
amyloids.[97] Despite this, what determines a Pin1 “client” has been called into 
question.[98] Putative Pin1 binding sites have been challenging to substantiate, 
such as the unconventional bivalent interaction as seen with protein kinase C 
where both the WW and PPIase domains bind to disparate sites on the protein,[99] 
 
 
Figure 1.7) Pin1 is required for conformational switching of phosphoserine-proline. 
Increased steric bulk and transient backbone interactions of the phosphate group 
dramatically slow the rate of intrinsic isomerization, when compared to the 
unphosphorylated dipeptide. Pin1 selectively recognizes the negative charge adjacent 
to the proline and removes the isomerization bottleneck. The cis and trans 
conformations are illustrated as an orange dotted line. 
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or the role in controlling phosphorylated tau function for microtubule assembly and 
stabilization.[100] 
 
Through the ability to control the folding or function of so many clients, PPIases 
have been suggested as potential drug targets for cancer, viral infection, 
neurodegeneration and other diseases. Indeed, Pin1 is one of the most widely 
over-expressed proteins in all cancers[101], including prostate, brain, breast, 
ovary, cervical and melanomas.[102] However, it has proven to be particularly 
challenging to target Pin1 with small molecules. The natural products, FK506 and 
rapamycin, do not effectively bind to Pin1 or inhibit its PPIase activity. As will be 
discussed in Chapter 4, attempts at developing synthetic inhibitors have not yet 
achieved good potency or selectivity. 
 
1.9 Analysis and Prospectus 
In this Chapter, I provide an introduction to the structure and function of the 
PPIases and their role(s) in disease. I also discussed how natural bifunctional 
molecules, such as FK506, have been key to discovering PPIases and 
understanding their roles. Moreover, I introduced how synthetic bifunctional 
molecules, inspired by FK506 and rapamycin, have subsequently been used in 
chemical biology strategies to bind two proteins simultaneously. Finally, the 
promise and particular challenge of Pin1 as a drug target in the PPIase superfamily 
was introduced. In the subsequent Chapters, I will describe my efforts to expand 
our knowledge of PPIases and their respective natural product inhibitors. I was 
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specifically interested in two emerging areas of PPIase research. In Chapter 2 and 
3, I develop a new way of using synthetic, bifunctional molecules to selectively 
target cells that express high levels of FKBP12. Those studies both extend the use 
of chemical biology approaches based on FK506, while also teaching us about the 
possible mechanisms of the natural product. In Chapter 4, I develop a novel way 
to exploit the natural products to design promising new inhibitors of Pin1. Then, in 
Chapter 5, I conclude with an analysis of the future of PPIase research. 
 
1.10 Notes 
This chapter represents a portion of the work published in “Dunyak, B.M. & 
Gestwicki, J.E. Peptidyl-Proline Isomerases (PPIases): Targets for Natural 
Products and Natural Product-Inspired Compounds. J. Med. Chem. In press. 
(2016).” 
 
1.11 References 
1. Fischer, G., Bang, H. & Mech, C. [Determination of enzymatic catalysis for 
the cis-trans-isomerization of peptide binding in proline-containing 
peptides]. Biomed Biochim Acta 43, 1101-11 (1984). 
2. Galat, A. Peptidylprolyl cis/trans isomerases (immunophilins): biological 
diversity--targets--functions. Curr Top Med Chem 3, 1315-47 (2003). 
3. Saibil, H. Chaperone machines for protein folding, unfolding and 
disaggregation. Nat Rev Mol Cell Biol 14, 630-42 (2013). 
4. Theuerkorn, M., Fischer, G. & Schiene-Fischer, C. Prolyl cis/trans 
isomerase signalling pathways in cancer. Curr Opin Pharmacol 11, 281-7 
(2011). 
5. Frausto, S.D., Lee, E. & Tang, H. Cyclophilins as modulators of viral 
replication. Viruses 5, 1684-701 (2013). 
6. Storer, C.L., Dickey, C.A., Galigniana, M.D., Rein, T. & Cox, M.B. FKBP51 
and FKBP52 in signaling and disease. Trends Endocrinol Metab 22, 481-
90 (2011). 
20 
 
7. Koren, J., 3rd et al. Bending tau into shape: the emerging role of peptidyl-
prolyl isomerases in tauopathies. Mol Neurobiol 44, 65-70 (2011). 
8. Makley, L.N. & Gestwicki, J.E. Expanding the number of 'druggable' 
targets: non-enzymes and protein-protein interactions. Chem Biol Drug 
Des 81, 22-32 (2013). 
9. Siekierka, J.J., Hung, S.H., Poe, M., Lin, C.S. & Sigal, N.H. A cytosolic 
binding protein for the immunosuppressant FK506 has peptidyl-prolyl 
isomerase activity but is distinct from cyclophilin. Nature 341, 755-7 
(1989). 
10. Kim, P.S. & Baldwin, R.L. Specific intermediates in the folding reactions of 
small proteins and the mechanism of protein folding. Annu Rev Biochem 
51, 459-89 (1982). 
11. Schonbrunner, E.R. et al. Catalysis of protein folding by cyclophilins from 
different species. J Biol Chem 266, 3630-5 (1991). 
12. Andreotti, A.H. Native state proline isomerization: an intrinsic molecular 
switch. Biochemistry 42, 9515-24 (2003). 
13. Zheng, H. et al. The prolyl isomerase Pin1 is a regulator of p53 in 
genotoxic response. Nature 419, 849-53 (2002). 
14. Girardini, J.E. et al. A Pin1/mutant p53 axis promotes aggressiveness in 
breast cancer. Cancer Cell 20, 79-91 (2011). 
15. He, Z., Li, L. & Luan, S. Immunophilins and parvulins. Superfamily of 
peptidyl prolyl isomerases in Arabidopsis. Plant Physiol 134, 1248-67 
(2004). 
16. Somarelli, J.A., Lee, S.Y., Skolnick, J. & Herrera, R.J. Structure-based 
classification of 45 FK506-binding proteins. Proteins 72, 197-208 (2008). 
17. Fulton, K.F., Jackson, S.E. & Buckle, A.M. Energetic and structural 
analysis of the role of tryptophan 59 in FKBP12. Biochemistry 42, 2364-72 
(2003). 
18. Rosen, M.K., Standaert, R.F., Galat, A., Nakatsuka, M. & Schreiber, S.L. 
Inhibition of FKBP rotamase activity by immunosuppressant FK506: 
twisted amide surrogate. Science 248, 863-6 (1990). 
19. Xu, G.G., Zhang, Y., Mercedes-Camacho, A.Y. & Etzkorn, F.A. A reduced-
amide inhibitor of Pin1 binds in a conformation resembling a twisted-amide 
transition state. Biochemistry 50, 9545-50 (2011). 
20. Howard, B.R., Vajdos, F.F., Li, S., Sundquist, W.I. & Hill, C.P. Structural 
insights into the catalytic mechanism of cyclophilin A. Nat Struct Biol 10, 
475-81 (2003). 
21. Keedy, D.A. et al. Mapping the conformational landscape of a dynamic 
enzyme by multitemperature and XFEL crystallography. Elife 4 (2015). 
22. DeCenzo, M.T. et al. FK506-binding protein mutational analysis: defining 
the active-site residue contributions to catalysis and the stability of ligand 
complexes. Protein Eng 9, 173-80 (1996). 
23. Behrsin, C.D. et al. Functionally important residues in the peptidyl-prolyl 
isomerase Pin1 revealed by unigenic evolution. J Mol Biol 365, 1143-62 
(2007). 
21 
 
24. Barman, A. & Hamelberg, D. Cysteine-mediated dynamic hydrogen-
bonding network in the active site of Pin1. Biochemistry 53, 3839-50 
(2014). 
25. Carmody, M., Mackrill, J.J., Sorrentino, V. & O'Neill, C. FKBP12 
associates tightly with the skeletal muscle type 1 ryanodine receptor, but 
not with other intracellular calcium release channels. FEBS Lett 505, 97-
102 (2001). 
26. Lyons, W.E., Steiner, J.P., Snyder, S.H. & Dawson, T.M. Neuronal 
regeneration enhances the expression of the immunophilin FKBP-12. J 
Neurosci 15, 2985-94 (1995). 
27. Hoeffer, C.A. et al. Removal of FKBP12 enhances mTOR-Raptor 
interactions, LTP, memory, and perseverative/repetitive behavior. Neuron 
60, 832-45 (2008). 
28. Shou, W. et al. Cardiac defects and altered ryanodine receptor function in 
mice lacking FKBP12. Nature 391, 489-92 (1998). 
29. Kozany, C., Marz, A., Kress, C. & Hausch, F. Fluorescent probes to 
characterise FK506-binding proteins. Chembiochem 10, 1402-10 (2009). 
30. Davies, T.H., Ning, Y.M. & Sanchez, E.R. A new first step in activation of 
steroid receptors: hormone-induced switching of FKBP51 and FKBP52 
immunophilins. J Biol Chem 277, 4597-600 (2002). 
31. Assimon, V.A., Southworth, D.R. & Gestwicki, J.E. Specific Binding of 
Tetratricopeptide Repeat Proteins to Heat Shock Protein 70 (Hsp70) and 
Heat Shock Protein 90 (Hsp90) Is Regulated by Affinity and 
Phosphorylation. Biochemistry 54, 7120-31 (2015). 
32. Cheung-Flynn, J. et al. Physiological role for the cochaperone FKBP52 in 
androgen receptor signaling. Mol Endocrinol 19, 1654-66 (2005). 
33. LeMaster, D.M. et al. Coupling of Conformational Transitions in the N-
terminal Domain of the 51-kDa FK506-binding Protein (FKBP51) Near Its 
Site of Interaction with the Steroid Receptor Proteins. J Biol Chem 290, 
15746-57 (2015). 
34. Blair, L.J., Baker, J.D., Sabbagh, J.J. & Dickey, C.A. The emerging role of 
peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid 
processing, and Alzheimer's disease. J Neurochem 133, 1-13 (2015). 
35. Jinwal, U.K. et al. The Hsp90 cochaperone, FKBP51, increases Tau 
stability and polymerizes microtubules. J Neurosci 30, 591-9 (2010). 
36. Chambraud, B. et al. A role for FKBP52 in Tau protein function. Proc Natl 
Acad Sci U S A 107, 2658-63 (2010). 
37. Giustiniani, J. et al. The FK506-binding protein FKBP52 in vitro induces 
aggregation of truncated Tau forms with prion-like behavior. FASEB J 29, 
3171-81 (2015). 
38. Giustiniani, J. et al. Immunophilin FKBP52 induces Tau-P301L 
filamentous assembly in vitro and modulates its activity in a model of 
tauopathy. Proc Natl Acad Sci U S A 111, 4584-9 (2014). 
39. Stocki, P. et al. Inhibition of the FKBP family of peptidyl prolyl isomerases 
induces abortive translocation and degradation of the cellular prion 
protein. Mol Biol Cell 27, 757-67 (2016). 
22 
 
40. Edlich, F. & Lucke, C. From cell death to viral replication: the diverse 
functions of the membrane-associated FKBP38. Curr Opin Pharmacol 11, 
348-53 (2011). 
41. Wang, P. & Heitman, J. The cyclophilins. Genome Biol 6, 226 (2005). 
42. Handschumacher, R.E., Harding, M.W., Rice, J., Drugge, R.J. & Speicher, 
D.W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. 
Science 226, 544-7 (1984). 
43. Fruman, D.A., Burakoff, S.J. & Bierer, B.E. Immunophilins in protein 
folding and immunosuppression. FASEB J 8, 391-400 (1994). 
44. Crompton, M. The mitochondrial permeability transition pore and its role in 
cell death. Biochem J 341 ( Pt 2), 233-49 (1999). 
45. Halestrap, A.P. & Brenner, C. The adenine nucleotide translocase: a 
central component of the mitochondrial permeability transition pore and 
key player in cell death. Curr Med Chem 10, 1507-25 (2003). 
46. Ward, B.K., Mark, P.J., Ingram, D.M., Minchin, R.F. & Ratajczak, T. 
Expression of the estrogen receptor-associated immunophilins, cyclophilin 
40 and FKBP52, in breast cancer. Breast Cancer Res Treat 58, 267-80 
(1999). 
47. Rahfeld, J.U. et al. Confirmation of the existence of a third family among 
peptidyl-prolyl cis/trans isomerases. Amino acid sequence and 
recombinant production of parvulin. FEBS Lett 352, 180-4 (1994). 
48. Mueller, J.W. et al. Characterization of novel elongated Parvulin isoforms 
that are ubiquitously expressed in human tissues and originate from 
alternative transcription initiation. BMC Mol Biol 7, 9 (2006). 
49. Surmacz, T.A., Bayer, E., Rahfeld, J.U., Fischer, G. & Bayer, P. The N-
terminal basic domain of human parvulin hPar14 is responsible for the 
entry to the nucleus and high-affinity DNA-binding. J Mol Biol 321, 235-47 
(2002). 
50. Fujiyama-Nakamura, S. et al. Parvulin (Par14), a peptidyl-prolyl cis-trans 
isomerase, is a novel rRNA processing factor that evolved in the 
metazoan lineage. Mol Cell Proteomics 8, 1552-65 (2009). 
51. Thiele, A. et al. Parvulin 17 promotes microtubule assembly by its 
peptidyl-prolyl cis/trans isomerase activity. J Mol Biol 411, 896-909 (2011). 
52. Kessler, D. et al. The DNA binding parvulin Par17 is targeted to the 
mitochondrial matrix by a recently evolved prepeptide uniquely present in 
Hominidae. BMC biology 5, 1 (2007). 
53. Stukenberg, P.T. & Kirschner, M.W. Pin1 acts catalytically to promote a 
conformational change in Cdc25. Mol Cell 7, 1071-83 (2001). 
54. Liou, Y.C. et al. Loss of Pin1 function in the mouse causes phenotypes 
resembling cyclin D1-null phenotypes. Proc Natl Acad Sci U S A 99, 1335-
40 (2002). 
55. Liu, J. et al. Calcineurin is a common target of cyclophilin-cyclosporin A 
and FKBP-FK506 complexes. Cell 66, 807-15 (1991). 
56. Brown, E.J. et al. A mammalian protein targeted by G1-arresting 
rapamycin-receptor complex. Nature 369, 756-8 (1994). 
23 
 
57. Harding, M.W., Galat, A., Uehling, D.E. & Schreiber, S.L. A receptor for 
the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. 
Nature 341, 758-60 (1989). 
58. Weiwad, M. et al. Comparative analysis of calcineurin inhibition by 
complexes of immunosuppressive drugs with human FK506 binding 
proteins. Biochemistry 45, 15776-84 (2006). 
59. Marz, A.M., Fabian, A.K., Kozany, C., Bracher, A. & Hausch, F. Large 
FK506-binding proteins shape the pharmacology of rapamycin. Mol Cell 
Biol 33, 1357-67 (2013). 
60. Ho, S. et al. The mechanism of action of cyclosporin A and FK506. Clin 
Immunol Immunopathol 80, S40-5 (1996). 
61. Sehgal, S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of 
action immunosuppressive effect results from blockade of signal 
transduction and inhibition of cell cycle progression. Clin Biochem 31, 335-
40 (1998). 
62. Faivre, S., Kroemer, G. & Raymond, E. Current development of mTOR 
inhibitors as anticancer agents. Nat Rev Drug Discov 5, 671-88 (2006). 
63. Yang, H. et al. mTOR kinase structure, mechanism and regulation. Nature 
497, 217-23 (2013). 
64. Spencer, D.M., Wandless, T.J., Schreiber, S.L. & Crabtree, G.R. 
Controlling signal transduction with synthetic ligands. Science 262, 1019-
24 (1993). 
65. Clackson, T. et al. Redesigning an FKBP-ligand interface to generate 
chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A 95, 
10437-42 (1998). 
66. Sakamoto, K.M. et al. Protacs: chimeric molecules that target proteins to 
the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc 
Natl Acad Sci U S A 98, 8554-9 (2001). 
67. Braun, P.D. et al. A bifunctional molecule that displays context-dependent 
cellular activity. J Am Chem Soc 125, 7575-80 (2003). 
68. Inoue, T., Heo, W.D., Grimley, J.S., Wandless, T.J. & Meyer, T. An 
inducible translocation strategy to rapidly activate and inhibit small 
GTPase signaling pathways. Nat Methods 2, 415-8 (2005). 
69. Corson, T.W., Aberle, N. & Crews, C.M. Design and Applications of 
Bifunctional Small Molecules: Why Two Heads Are Better Than One. ACS 
Chem Biol 3, 677-692 (2008). 
70. Thomis, D.C. et al. A Fas-based suicide switch in human T cells for the 
treatment of graft-versus-host disease. Blood 97, 1249-57 (2001). 
71. Gray, D.C., Mahrus, S. & Wells, J.A. Activation of specific apoptotic 
caspases with an engineered small-molecule-activated protease. Cell 142, 
637-46 (2010). 
72. Banaszynski, L.A., Chen, L.C., Maynard-Smith, L.A., Ooi, A.G. & 
Wandless, T.J. A rapid, reversible, and tunable method to regulate protein 
function in living cells using synthetic small molecules. Cell 126, 995-1004 
(2006). 
24 
 
73. Grimley, J.S., Chen, D.A., Banaszynski, L.A. & Wandless, T.J. Synthesis 
and analysis of stabilizing ligands for FKBP-derived destabilizing domains. 
Bioorg Med Chem Lett 18, 759-61 (2008). 
74. Keenan, T. et al. Synthesis and activity of bivalent FKBP12 ligands for the 
regulated dimerization of proteins. Bioorg Med Chem 6, 1309-35 (1998). 
75. Armistead, D.M. et al. Design, synthesis and structure of non-macrocyclic 
inhibitors of FKBP12, the major binding protein for the 
immunosuppressant FK506. Acta Crystallogr D Biol Crystallogr 51, 522-8 
(1995). 
76. Holt, D.A. et al. Design, synthesis, and kinetic evaluation of high-affinity 
FKBP ligands and the X-ray crystal structures of their complexes with 
FKBP12. Journal of the American Chemical Society 115, 9925-9938 
(1993). 
77. DeRose, R., Miyamoto, T. & Inoue, T. Manipulating signaling at will: 
chemically-inducible dimerization (CID) techniques resolve problems in 
cell biology. Pflugers Arch 465, 409-17 (2013). 
78. Gestwicki, J.E., Crabtree, G.R. & Graef, I.A. Harnessing chaperones to 
generate small-molecule inhibitors of amyloid beta aggregation. Science 
306, 865-9 (2004). 
79. Winter, G.E. et al. DRUG DEVELOPMENT. Phthalimide conjugation as a 
strategy for in vivo target protein degradation. Science 348, 1376-81 
(2015). 
80. Romano, S. et al. FK506 binding proteins as targets in anticancer therapy. 
Anticancer Agents Med Chem 10, 651-6 (2010). 
81. Harikishore, A. & Yoon, H.S. Immunophilins: Structures, Mechanisms and 
Ligands. Curr Mol Pharmacol 9, 37-47 (2015). 
82. Yamaguchi, T., Kurisaki, A., Yamakawa, N., Minakuchi, K. & Sugino, H. 
FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin 
type I receptor. J Mol Endocrinol 36, 569-79 (2006). 
83. Pratt, W.B. & Toft, D.O. Steroid receptor interactions with heat shock 
protein and immunophilin chaperones. Endocr Rev 18, 306-60 (1997). 
84. Jin, Y.J. & Burakoff, S.J. The 25-kDa FK506-binding protein is localized in 
the nucleus and associates with casein kinase II and nucleolin. Proc Natl 
Acad Sci U S A 90, 7769-73 (1993). 
85. Davis, E.C., Broekelmann, T.J., Ozawa, Y. & Mecham, R.P. Identification 
of tropoelastin as a ligand for the 65-kD FK506-binding protein, FKBP65, 
in the secretory pathway. J Cell Biol 140, 295-303 (1998). 
86. Bush, K.T., Hendrickson, B.A. & Nigam, S.K. Induction of the FK506-
binding protein, FKBP13, under conditions which misfold proteins in the 
endoplasmic reticulum. Biochem J 303 ( Pt 3), 705-8 (1994). 
87. Cabral, W.A. et al. Abnormal type I collagen post-translational modification 
and crosslinking in a cyclophilin B KO mouse model of recessive 
osteogenesis imperfecta. PLoS Genet 10, e1004465 (2014). 
88. Harrell, J.M. et al. All of the protein interactions that link steroid 
receptor.hsp90.immunophilin heterocomplexes to cytoplasmic dynein are 
common to plant and animal cells. Biochemistry 41, 5581-7 (2002). 
25 
 
89. Kim, J. et al. Overexpressed cyclophilin B suppresses apoptosis 
associated with ROS and Ca2+ homeostasis after ER stress. J Cell Sci 
121, 3636-48 (2008). 
90. Colgan, J. et al. Cyclophilin A regulates TCR signal strength in CD4+ T 
cells via a proline-directed conformational switch in Itk. Immunity 21, 189-
201 (2004). 
91. Jin, Z.G. et al. Cyclophilin A is a secreted growth factor induced by 
oxidative stress. Circ Res 87, 789-96 (2000). 
92. Yurchenko, V., Constant, S., Eisenmesser, E. & Bukrinsky, M. Cyclophilin-
CD147 interactions: a new target for anti-inflammatory therapeutics. Clin 
Exp Immunol 160, 305-17 (2010). 
93. Nigro, P., Pompilio, G. & Capogrossi, M.C. Cyclophilin A: a key player for 
human disease. Cell Death Dis 4, e888 (2013). 
94. Du, H. et al. Cyclophilin D deficiency attenuates mitochondrial and 
neuronal perturbation and ameliorates learning and memory in 
Alzheimer's disease. Nat Med 14, 1097-105 (2008). 
95. Schutkowski, M. et al. Role of phosphorylation in determining the 
backbone dynamics of the serine/threonine-proline motif and Pin1 
substrate recognition. Biochemistry 37, 5566-75 (1998). 
96. Ryo, A., Liou, Y.C., Lu, K.P. & Wulf, G. Prolyl isomerase Pin1: a catalyst 
for oncogenesis and a potential therapeutic target in cancer. J Cell Sci 
116, 773-83 (2003). 
97. Driver, J.A., Zhou, X.Z. & Lu, K.P. Pin1 dysregulation helps to explain the 
inverse association between cancer and Alzheimer's disease. Biochim 
Biophys Acta 1850, 2069-76 (2015). 
98. Eichner, T., Kutter, S., Labeikovsky, W., Buosi, V. & Kern, D. Molecular 
Mechanism of Pin1-Tau Recognition and Catalysis. J Mol Biol 428, 1760-
75 (2016). 
99. Abrahamsen, H. et al. Peptidyl-prolyl isomerase Pin1 controls down-
regulation of conventional protein kinase C isozymes. J Biol Chem 287, 
13262-78 (2012). 
100. Kutter, S., Eichner, T., Deaconescu, A.M. & Kern, D. Regulation of 
Microtubule Assembly by Tau and not by Pin1. J Mol Biol 428, 1742-59 
(2016). 
101. Ibanez, K., Boullosa, C., Tabares-Seisdedos, R., Baudot, A. & Valencia, 
A. Molecular evidence for the inverse comorbidity between central 
nervous system disorders and cancers detected by transcriptomic meta-
analyses. PLoS Genet 10, e1004173 (2014). 
102. Bao, L. et al. Prevalent overexpression of prolyl isomerase Pin1 in human 
cancers. Am J Pathol 164, 1727-37 (2004). 
 
 
26 
 
 
 
 
Chapter 2  
Design of naturally inspired bifunctional molecules 
 
2.1 Abstract 
Inspired by the natural product FK506, we designed a series of bifunctional 
molecules composed of an FKBP ligand and HIV protease inhibitor to explore ways 
of engineering cyto-selectivity. Similar to cyto-selective targeting of bi-specific 
antibodies that rely on co-expression of two cell-surface proteins, we demonstrate 
that these small molecules possess affinity for two cytoplasmic proteins. We 
envisioned a model in which coincident, high-level expression of both protein 
targets - such as in HIV-infected lymphocytes - would drive selective compound 
targeting and sequestration. One end of the bifunctional molecules consisted of a 
ligand for FKBP12, either FK506 itself or a Synthetic Ligand for FKBP (SLF), to 
provide either tight or weak binding, respectively. On the opposite end of the 
molecule, we attached the core of the FDA-approved, HIV protease inhibitor, 
amprenavir. We chose this starting point because the core of amprenavir has 
modest efficacy against HIV protease but its affinity is highly variable depending 
on substitution at the nearby amine. Thus, by making substitutions in this linker 
region, we envisioned “tuning” the affinity for HIV protease while linking each end 
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of the bifunctional molecule. Amino acid linkers were incorporated to readily 
introduce functional groups with different hydrophobicities, flexibilities, geometries 
and chain lengths. Using biochemical assays, we characterized our library of 
bifunctional molecules and demonstrated that they possess a range of affinities for 
both FKBP12 and HIV protease. In Chapter 3, we demonstrate their ability for cyto-
selective, intracellular targeting. 
 
2.2 Introduction 
2.2.1 Cyto-selective Targeting via Bifunctional Molecules 
Bi-specific antibodies differentiate between cells by exploiting the target’s 
expression of two proteins that are not co-incident on other cells.[1] Optimization 
of these drugs often hinges on maximizing their avidity, while reducing interactions 
with bystander cells.[2] Here, we wondered whether a similar approach might be 
used to drive the cyto-selectivity of a small molecule. One potential advantage of 
this idea would be that small molecules can access intracellular proteins, 
expanding the choices for discriminating between cell types. To this end, we were 
inspired by the natural product, FK506. This molecule is naturally bi-specific; it 
binds FK506-binding protein (FKBP12) with one chemical “face” and calcineurin 
with the other. FKBP has high affinity (KD ~ 0.6 nM)[3] for FK506 and this drug-
protein pair recruits calcineurin into a remarkably stable, ternary complex (Kapp ~ 6 
to 30 nM).[3, 4] This unusual binding mode may also impart cyto-selectivity 
because FK506 is principally sequestered into lymphocytes and red blood cells 
after oral administration,[5, 6] perhaps because these cell types express relatively 
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high concentrations of the two target proteins. To better understand this natural 
mechanism and explore ways of possibly engineering bi-specific small molecules, 
we chose a model system based on the human immunodeficiency virus (HIV) 
protease.  
 
2.2.2 HIV Protease Inhibitors have Poor Pharmacological Properties 
Although they are clinically effective, HIV protease inhibitors are poorly cell 
penetrant and rapidly metabolized.[7] Critical for the life cycle and replication of 
HIV virion particles, HIV protease cleaves synthesized Gag-Pol polyprotein into 
newly formed mature proteins.[8] Without active protease, HIV is unable to 
replicate and therefore unable to infect new cells.[9] Thus, HIV protease has been 
a critical target for antiretroviral therapies. HIV protease is an aspartyl protease 
that exists as a small homodimer consisting of 99 amino acids per monomer. 
Effective inhibitors of this protease have typically been peptidomimetics that mimic 
the binding conformation of native substrates.[10] The efficacy of the HIV protease 
inhibitors has resulted in their integral role in Highly Active Anti-Retroviral Therapy 
(HAART), a cocktail therapy approach to reduce viral load. Despite their utility, use 
of HIV protease inhibitors is often complicated by their relatively poor ADME  
properties.[7] In general, the protease inhibitors are often plasma bound (~99%) 
and are extensively degraded by first pass metabolism; they are excellent 
substrates for multiple cytochrome P450 enzymes (primarily 3A4, also 2D6 and 
2D9) and the P-glycoprotein efflux pump. For these reasons, maximizing 
sequestration and tissue distribution has been essential. Low intracellular 
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concentration often limits efficacy and allows for rapid accumulation of resistance-
conferring mutations.[11] Numerous approaches have been attempted to increase 
intracellular concentration and bioavailability of these drugs, some of which include 
prodrug strategies, PEGylation  and ritonavir co-administration to inhibit metabolic 
enzymes and minimize first pass metabolism.[12] 
 
We hypothesized that an “FK506-like” molecule capable of simultaneously binding 
FKBP12 and HIV protease might be selectively retained in cells that express both 
targets. To test this idea, we synthesized bifunctional molecules composed of an 
FKBP12 ligand and an HIV protease inhibitor attached by a modular linker. In this 
collection, we systematically varied the affinity of the molecules for FKBP12 and 
HIV protease, creating a suite of tools that were validated biochemically. Later, we 
discuss these molecules and ask how bivalency correlates with cyto-selectivity.  
 
2.3 Results 
2.3.1 General Overview of Bifunctional Approach 
We envisioned the synthesis of compounds 9a-f and 10a-f using a general strategy 
composed of three major components (Figure 2.1). On one end would be a ligand 
 
Figure 2.1) Schematic representation of bifunctional molecules. Ligands targeting 
FKBPs are connected to a small molecule targeting a protein of interest and connected 
via a short linker. 
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for FKBP12, either FK506 itself or SLF. On the other end is the ligand of interest, 
in this case an HIV protease inhibitor. Connecting the two is a short linker allowing 
for additional tuning of the affinity for each respective target.  
 
For FKBP ligands, we chose to use FK506 and SLF. SLF is composed of only one 
half of FK506 and it is known to have a significantly weaker affinity for FKBP12.[13] 
Thus, using FK506 or SLF as one “end” of the molecule would be expected to 
provide either tight or weak binding to FKBP12, respectively. To avoid the 
immunosuppressive effects of using FK506, we took advantage of observations 
that modification of the extra-cyclic alkene destroys its affinity for calcineurin, but 
does not alter its tight binding to FKBP12.[14]  
 
2.3.2 Synthesis of Bifunctional Molecules 
To synthesize the FK506 building block 2, microwave-assisted Grubbs’ cross 
metathesis chemistry[15] was used to install 4-pentenoic acid at the terminal 
alkene in one step with modest yield (3hr, 80°C, 60%). Likewise, we modified SLF 
at the aniline with excess succinic anhydride in anhydrous DCM to produce a 
modified SLF (4) intermediate containing a terminal carboxylic acid in quantitative 
yield (Figure 2.2). These two compounds provided FKBP12-binding motifs for 
further coupling. On the opposite end of the molecule, we first assembled the 4-
methoxy derivative of the core (8) of the FDA -approved, HIV protease inhibitor, 
amprenavir. We chose this starting point because the core of amprenavir has 
modest efficacy against HIV protease (Ki ≈ 180 nM) but its affinity is highly tunable 
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by substitution at the nearby amine.[16-18] Accordingly, the core of amprenavir 
was synthesized by a known route starting from the epoxide (Figure 2.3)[19] then 
functionalized at the pseudo N-terminus. Thus, by making substitutions in this 
region, we envisioned “tuning” the affinity for HIV protease. Amino acids were 
chosen for the linker because the side chains could be used to readily introduce 
functional groups with different hydrophobicities, flexibilities, geometries and chain 
lengths (Figure 2.4). Based on well-established structure-activity relationships 
 
 
Figure 2.2) Synthesis of the FKBP-Binding Motif for Bi-Specific Library Generation (i) 
4-pentenoic acid (3 eq), Grubbs 2nd Generation Catalyst (0.1eq), DCM, N2, microwave 
irradiation for 3hr  at 80°C. (ii) Succinic anhydride (3 eq), DIEA  (1eq), DCM. 
 
Figure 2.3) Synthesis of the Amprenavir Core (i) (2S,3S)-1,2-Epoxy-3-(Boc -amino)-4-
phenylbutane (1 eq), isobutylamine (5 eq), isopropanol. (ii) 4-methoxybenzene sulfonyl 
chloride (1.1 eq), cesium carbonate, 1:1 DCN:water. (iii) 50% TFA /DCM. 
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(SAR) for HIV protease inhibitors,[16-18] we hypothesized that small alkyl and 
benzyl substitutions would be tolerated, while the proline and lysine analogues 
might not. Finally, the modified amprenavir derivatives were coupled to the free 
acid of the modified FK506 or SLF motifs and the final products purified by HPLC  
to yield twelve bifunctional molecules (9a-f and 10a-f) in 20 to 40% overall yield. 
As a control for later experiments, we synthesized 4-methoxy-amprenavir (herein 
amprenavir) that contains a tetrahydrofuranyl urethane moiety in the place of our 
linker (Figure 2.5). In part, we chose to use this variant of amprenavir rather than 
 
 
Figure 2.4) Focused Libary Design of Bifunctional Molecules. Modular methods were 
used to assemble molecules containing either FK506 (series 1) or SLF (series 2) 
attached to an Amprenavir core. 
 
Figure 2.5) Synthesis of Amprenavir. (i) (S)-(+)3-hydroxytetrahydrofuran (1eq), 
disuccinimidyl carbonate(1.5eq), DIEA (2eq), DCM. 
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the FDA-approved compound because it has been shown to be equivalent in cell-
based assays and is synthetically tractable. 
 
2.3.4 Biochemical Characterization of the Bifunctional Library 
With this library in-hand, we first measured the affinity of the compounds for 
purified FKBP12 in vitro. We adapted a previously reported fluorescence 
polarization (FP)   assay based on the SLF scaffold shown in Figure 2.2. Amide 
coupling to 4’-(aminomethyl)-fluorescein resulted in the fluorescent tracer (12 
Figure 2.6A), which bound to FKBP12 with a KD = 9.6 ± 1.6 nM (Figure 2.6B). To 
ensure the fluorescent tracer was binding to FKBP12 without significant affinity 
difference due to the fluorescein modification, the interaction was competed 
against unmodified FK506 and SLF, and calculated Ki values (5.1 ± 2.4 nM and 25 
± 14 nM, respectively) were found to be in good agreement with the literature 
 
Figure 2.6) Development of a Fluorescence Polarization Assay for FKBP12 Binding. 
A) 4’-(aminomethyl)-fluorescein (1.1 eq), HATU  (1.3 eq), DIEA (3 eq), DMF. B) 
Fluorescent tracer binds with high affinity to FKBP12. C) FK506 and SLF compete with 
the fluorescent tracer for binding to FKBP12. Results are the average of at least three 
independent experiments performed in triplicate. Error bars are SEM. 
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(Figure 2.6C).[20, 21] Subsequent determination of Ki values for the library were 
likewise performed by competition assays in the FP platform. We found that the Ki 
values were principally determined by the identity of the FKBP12 ligand, either 
FK506 or SLF (Figure 2.7). Specifically, compounds 9a-f had Ki values ranging 
between 19 and 29 nM, while 10a,b,d-f had values ranging from 40 to 93 nM. 
These affinities were similar to those of unmodified FK506 or SLF (Figure 2.6C), 
suggesting that neither the linker nor the pendant HIV protease inhibitor 
dramatically impacted apparent affinity. This result might be expected because the 
binding site on FKBP12 is highly exposed[22, 23] and many studies on bifunctional 
FKBP12 ligands have shown similar modularity.[24-27] Because of non-specific 
tracer binding, we had to measure the affinity of 10c for FKBP12 using a surface-
plasmon resonance (SPR)  platform instead of FP. FKBP12 was immobilized with 
traditional amide coupling and the rate of ligand association followed by 
dissociation was monitored across a range of concentrations. Using this approach 
 
Figure 2.7) Competition for binding of an SLF tracer to human FKBP12. FK506 
derivatives (blue, full circle representation) bind approximately 5-fold higher than their 
SLF counterparts (orange, half-circle representation). Results are the average of at 
least three independent experiments performed in triplicate. Error bars are SEM. 
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we found that 10c had a similar affinity for FKBP12 as the other molecules in the 
series (KD = 51 ± 50 nM, Figure 2.8).  
 
To analyze binding of the full compound collection to HIV protease, we employed 
a standard enzymatic cleavage assay.[28] We first tested our control amprenavir 
derivatives, 8 and 11, which were incubated with HIV protease and a FRET-
labelled substrate and inhibition curves generated from endpoint measurements 
(Figure 2.9) during the linear phase of the assay. As expected, the 
tetrahydrofuranyl urethane moiety provided a significant increase in potency (over 
300-fold). This suggested that the linkers we chose could dramatically alter affinity 
for HIV protease. We then tested compounds 9a-f and 10a-f in the assay (Figure 
2.10). Consistent with previous SAR,[16-18] we found that the identity of the linker 
had a substantial impact on activity. Specifically, the Ki values varied by more than 
two orders-of-magnitude; compound 10a had a Ki of 1.3 ± 0.3 nM, while compound 
9d had a Ki of 170 ± 39 nM. Replacing FK506 with SLF did not seem to significantly 
 
Figure 2.8) Binding of 10c to FKBP12 Using Surface Plasmon Resonance. Compound 
10c was titrated across immobilized FKBP12 (legend in nM). Rate of association then 
dissociation was calculated to determine the KD (51 ± 50 nM). 
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impact anti-protease activity, likely because that portion of the molecule is too far 
from the active site. The inhibitory activity of protease inhibitors is known to 
correlate with binding affinity,[29] thus, compounds 9a-f and 10a-f appear to 
provide a range of affinity values for each protein target. To further confirm the 
affinity range of the library for HIV protease, we again used the SPR platform as a 
secondary binding assay (Figure 2.11). In this case, HIV protease was immobilized 
 
Figure 2.10) Apparent Affinity of the Library for HIV Protease. Identity of the linker of 
each bifunctional molecule impacts the compounds affinity for HIV protease by over 
10-fold, while the FKBP ligand (FK506 – blue circle, SLF – orange half-circle) did not 
seem to have an effect. Results are the average of at least three independent 
experiments performed in triplicate. Error bars are SEM. 
 
Figure 2.9) Derivatives of Amprenavir potently inhibit HIV protease in the FRET 
cleavage assay. The Amprenavir core 8 inhibits HIV protease with a Ki = 180±20 nM, 
while Amprenavir (11) inhibits HIV protease with a Ki = 0.48±0.06 nM. Results are the 
average of at least three independent experiments performed in triplicate. Error bars 
are SEM. 
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and compound 10c was titrated across the chip surface. As expected, compound 
10c bound with tight affinity to HIV protease (KD = 42 ± 28 nM), confirming the 
affinities determined in the protease cleavage assay. The affinities calculated for 
each ligand for both FKBP12 and HIV protease are summarized in Table 2.1. 
 
2.3.5 Formation of a Ternary Complex Using Synthetic Bifunctional Molecules 
To ensure that simultaneous binding to both FKBP and HIV protease does not 
impair the ability of the ligands to effectively bind each target, FKBP12 was 
introduced into the protease cleavage assay. A set of compounds from the library 
 
Figure 2.11) Binding of 10c to HIV protease. Compound 10c was titrated across 
immobilized HIV protease (legend in nM). Rate of association then dissociation was 
calculated to determine the KD (42 ± 28 nM). 
 
 
Table 2.1) Summary of the biochemical characterization of the bifunctional library 
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was chosen to span a wide range of affinities and tested with the addition of 
FKBP12 (1M) at a concentration sufficient for binding. As expected, binding to 
FKBP12 did not significantly impact the inhibitory activity of these ligands against 
HIV protease (Figure 2.12). The parent HIV protease inhibitor amprenavir was also 
included as a control to show that FKBP12 does not affect the assay. While the 
addition of FKBP12 into the HIV protease cleavage assay provided evidence that 
these ligands could bind both protein partners without effecting their activity, we 
 
Figure 2.12) Simultaneous Binding to FKBP12 and HIV Protease does not impair anti-
protease activity. Addition of FKBP12 (1M) does not impact the apparent Ki of the 
library against HIV protease. Results are the average of at least two independent 
experiments performed in triplicate. Error bars are SEM. 
 
Figure 2.13) Ternary complex formation between HIV Protease and FKBP12. A) 
Schematic for ternary complex formation mediated by bifunctional ligands. B) FKBP12 
association and dissociation after addition of 9b to the immobilized HIV protease 
surface. 
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still desired to show their ability for form a ternary complex like other CIDs. We 
again turned to the SPR platform, this time using the immobilized HIV protease 
surface, first injecting the bifunctional ligand 9b (which possesses high affinity for 
both FKBP12 and HIV protease) then injecting FKBP12. Binding of 9b to HIV 
protease followed by addition of FKBP12 allows for formation of the ternary 
complex on the chip surface. Rapid, subsequent injections are required so that 
HIV protease is occupied with ligand and can then bind FKBP12, before 
dissociation can occur. Including 9b in the buffer instead would saturate both 
FKBP12 and HIV protease with ligand before the ternary complex is able to form 
(Figure 2.13A). Adding a combination of FKBP12 and 9b to immobilized HIV 
protease showed that FKBP12 doesn’t bind to HIV protease in the absence of 9b, 
but that a stable ternary complex is formed in the presence of the molecule (Figure 
2.13B). We also observed a significantly increased response on binding due to the 
large increase in apparent molecular mass from ternary complex formation as 
compared to ligand alone binding to protein.  
 
2.4 Discussion 
Inspired by FK506, we wanted to explore the design principles that might govern 
cyto-selectivity. Accordingly, we synthesized bifunctional inhibitors in which the 
affinities for two target proteins, HIV protease and FKBP12, were systematically 
varied. We gained control over the FKBP12 binding by using either FK506 or the 
weaker ligand, SLF, while affinity for HIV protease was tuned by installing linkers 
at a region that was known to impact binding. Using in vitro assays, we confirmed 
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that the affinities sampled a wide range, which allow us to ask how affinity 
correlates with cellular permeability in Chapter 3. These bifunctional ligands are 
additionally able to bind both FKBP12 and HIV protease, as observed in our in vitro 
assays. 
 
We anticipate that this strategy may be beneficial in other situations in which 
therapeutics possess poor pharmacodynamic properties or need to be guided to a 
specific cell type with precision. The clear disadvantages of this approach are that 
the resulting molecules are large and complex, with predicted physical properties 
that do not correlate well with oral bioavailability.[30] Like the original inspiration, 
FK506, effective bi-specific molecules may require cyclization[31, 32] or further 
engineering to incorporate the favorable valency features into a more amenable 
scaffold. 
 
2.5 Methods 
2.5.1 Plasmid Generation and Protein Purification 
Wild-type FKBP12 cDNA was obtained from Addgene (#20211) and cloned into 
the pMCSG7 vector using ligation independent cloning (Fwd: 5’-TAC TTC CAA 
TCC AAT GCT ATG GGA GTG CAG GTG GAA ACC ATC TCC-3’, Rev: 5’-TTA 
TCC ACT TCC AAT GTT ATC ATT CCA GTT TTA GAA GCT CCA CAT CGA A 
G-3’) for bacterial expression and purification. For cell-based studies, FKBP12 was 
cloned into the pcDNA3 mCherry ligation independent cloning vector (Fwd: 5’-TAC 
TTC CAA TCC AAT GCC ACC ATG GGA GTG CAG GTG GAA ACC ATC TCC-
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3’, Rev: 5’-CTC CCA CTA CCA ATG CCT TCC AGT TTT AGA AGC TCC ACA 
TCG AAG-3’). The GFP-HIV protease fusion construct was originally purchased 
from Addgene (#20253) and subcloned into the pcDNA5/FRT/TO vector with 
BamHI/XhoI restriction sites (Fwd: 5’- ATA GGA TCC ATG GTG AGC AAG GGC 
GAG GAG CT-3’, Rev: 5’- CTT ACT CGA GTT AGG CCG CCA GTG TGA TGG 
A-3’).  
 
FKBP12 was transformed into E. coli BL21(DE3) cells and grown in Terrific Broth 
for six hours at 37 °C, followed by induction with 1 mM IPTG at 20 °C for 12 hours. 
Cells were collected, lysed by sonication (100 mM Tris, 100 mM NaCl, 30 mM 
Imidazole, pH 8.0) and 6xHis-FKBP12 was bound on Ni-NTA resin. Resin was 
washed once (100 mM Tris, 500 mM NaCl, 100 mM Imidazole, pH 8.0) and eluted 
(100 mM Tris, 500 mM NaCl, 300 mM Imidazole, pH 8.0) before subsequent TEV 
protease cleavage of the 6xHis-tag. Purified protein was dialyzed into 50 mM 
HEPES, 100 mM NaCl, pH 7.4 overnight. 
 
HIV Protease Q7K expressed from the pET28a vector was purified from E. coli 
BL21(DE3) cells grown in Terrific Broth for six hours at 37 °C, followed by induction 
with 1 mM IPTG at 30 °C for 4 hours. Cells were collected, homogenized at 15,000 
PSI in Extraction Buffer (20 mM Tris, 1 mM EDTA, 5 mM DTT, pH 7.5) and 
centrifuged to obtain HIV Protease as pelleted inclusion bodies. Pellet was re-
suspended in Extraction Buffer + 2M Urea, centrifuged and the remaining inclusion 
bodies were solubilized in 1:1 Extraction Buffer:Acetic Acid (40 mL/L of initial 
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culture). The mixture was centrifuged to remove insoluble lipids and the 
supernatant was applied to SP-Sephadex resin and stirred for 30 minutes at 4 °C. 
Resin was washed with Buffer A (20 mM MES, 1 mM Glycine-glycine, 6 M Urea, 
pH 6.5), Buffer B (20 mM Tris, 1 mM Glycine-glycine, 6 M Urea, pH 9) until pH 7 
and eluted with Buffer C (20 mM MES, 1 mM Glycine-glycine, 6 M Urea, 500 mM 
NaCl, pH 6.5). Eluted protein was bound to Ni-NTA Resin, washed with Buffer A, 
Buffer B and Buffer C and then eluted with Buffer D + 300 mM Imidazole. Elution 
was acidified with a small volume of acetic acid to pH 2 and DTT was added to 5 
mM. Unfolded protein was concentrated and then refolded by rapid dilution into 10 
mM formic acid, slowly adjusted to pH 7.5 with sodium acetate and NaCl was 
added to 1 M to precipitate inactive protease. Folded protein was dialyzed into 
Refolding Buffer (50 mM sodium acetate, 5 mM DTT, 10% Glycerol, 5% Ethylene 
Glycol, pH 5.5) overnight. 
 
2.5.2 FKBP12 Fluorescence Polarization Assay 
Binding to FKBP12 was measured by fluorescence polarization. The assay was 
performed at 60 μL final volume in PBS (Gibco) with 0.01% Triton X-100 using 
Corning 384-well flat-bottom black plates. For initial binding analysis of the 
fluorescent compound, recombinant FKBP12 was serially diluted 2-fold from 80 
μM initial concentration and then 15 μL added to each well for a top concentration 
of 20 μM. Fluorescent ligand 6 was initially dissolved in DMSO at 100 μM then 
dissolved 1000-fold into assay buffer and 15 μL of this solution was added to each 
well to give a final concentration of 25 nM. Finally, 30 μL of assay buffer with 4% 
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DMSO was added to each well to give a final volume of 60 μL with 2% DMSO. The 
plate was covered and equilibrated at room temperature for 30 minutes then read 
on a SpectraMax M5 at wavelength 488/515 ex/em. 
 
Competition experiments were performed under similar conditions. Separate 
solutions of FKBP12 and fluorescent ligand 6 at 100 μM were prepared and then 
15 μL of both was added to each well. Under these conditions, the majority of the 
fluorescent ligand would be bound to FKBP12. Compounds were initially dissolved 
in DMSO to 250 μM, serially diluted 3-fold, then diluted to 10 μM with assay buffer 
and 30 µL was added to each well to a final top concentration of 5 μM and 2% 
DMSO. The assay was equilibrated at room temperature for 30 minutes and then 
read as before. 
 
2.5.3 HIV Protease Enzymatic Cleavage Assay 
The HIV protease cleavage assay was performed as previously described.[28] 
Protease Substrate 1, RE(edans)SQNYPIVQK(dabcyl)R, was purchased from 
Sigma and Corning Low Volume Round-Bottom Black plates were used. In brief, 
recombinant HIV protease was diluted into Buffer P (100 mM sodium acetate, 1 M 
NaCl, 1 mM EDTA, 1 mM DTT, 20% Glycerol, 0.1% w/v CHAPS, pH 4.7) to an 
initial concentration of 60 nM and 5 μL was added to each well. Compounds were 
4-fold serially diluted from 1 mM in DMSO and then diluted 100-fold with assay 
buffer to 10 μM top concentration before 2 μL was added to each well. After 
compound addition, either 1 μL ddH2O or PEG-400 (final concentration 0.2% v/v 
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to improve solubility) was added to each well and plates were incubated for 30 
minutes at room temperature. After incubation, a fluorescent substrate solution (5 
μM) was prepared in assay buffer and 12 μL was rapidly added to each well. The 
assay plate was immediately shaken for 5 seconds in a SpectraMax M5 plate 
reader and monitored at 340/490 nm with a 475 cutoff filter for 30 minutes. 
Inhibition curves were plotted from the final timepoint after background subtraction 
of the fluorescent signal at assay initiation. 
 
2.5.4 Surface Plasmon Resonance 
SPR studies were conducted on a Biacore T100 instrument using a CM5 sensor 
chip. The nucleotide-binding domain of Hsp72 was used as a non-binding 
reference protein for background subtraction. Protein immobilization was 
performed using standard amine-coupling strategies and approximately 1500 RU 
was immobilized on each channel. PBS (Gibco) with 1% DMSO was used as a 
running buffer at a flowrate of 50 μL/min. Compounds were 2-fold serially diluted 
in DMSO and diluted 1000-fold in PBS for a final DMSO concentration of 1%. Each 
compound concentration was injected across the chip surface in duplicate with a 
5 minute association then dissociation phase. Between injections the protein 
surface was regenerated with two rapid 15 second injections of 20% ethanol in 
ddH2O. Blank injections of PBS plus 1% DMSO were performed at the beginning 
and end of each run to ensure adequate regeneration conditions and for 
background correction. Data was background corrected and blank injections were 
subtracted before importing into GraphPad Prism 6 and fit to the nonlinear 
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‘Association then dissociation’ algorithm with a robust fit setting. Affinities were 
calculated as the mean KD value of all fits across the dosing scheme and the error 
represented as the difference between the calculated KD and the value of the most 
extreme single fit. 
 
2.5.5 Synthetic Methods 
(E)-5-[(1R,9S,12S,13R,14S,17R,21S,23S,24R,25S,27R,E)-12-[(E)-2-
[(1R,3R,4R)-4-Hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-1,14-dihydroxy-
23,25-dimethoxy-13,19,21,27-tetramethyl-2,3,10,16-tetraoxo-11.28-dioxa-4-
azatricyclo[22.3.1.04,9]octacos-18-en-17-yl]-3-pentenoic acid (2) 
FK506 (1) was modified at the pendant alkene as previously described.[15] 
(i) 1 (20 mg, 0.025 mmol, 1 eq., LC Chemicals) and 4-pentenoic acid (7.5 mg, 
0.075 mmol, 3 eq., Sigma) in 0.5 mL anhydrous dichloromethane were added in a 
microwave vial, capped and sparged with dry N2. A solution of Grubbs 2nd 
Generation Catalyst (2.1 mg, 0.0025 mmol, 0.1eq., Sigma) was prepared in 0.5 
mL anhydrous dichloromethane and added under nitrogen. The mixture was 
placed in a microwave (Biotage) and irradiated with stirring for 3 hours at 80 °C. 
Afterwards, the vial was uncapped and ISOLUTE Si-Thiol was added (200mg, 
Biotage) to scavenge residual catalyst. The solution was filtered, solvent removed 
and purified by HPLC (40%-60% yield). 1H NMR (400 MHz, DMSO) δ 6.98 (s, 1H), 
6.57 (s, 1H) 5.63 (ddd, J = 16.8, 10.5, 5.9 Hz, 1H), 5.19 (d, J = 4.5 Hz, 1H), 5.15 – 
4.85 (m, 4H), 4.69 (dd, J = 38.0, 9.9 Hz, 2H), 4.41 (s, 1H), 4.19 (b, 1H), 4.18 (d, J 
= 13.4 Hz, 2H), 3.83 (s, 1H), 3.63 – 3.36 (m, 3H), 3.36 – 3.12 (m, 11H), 2.88 (s, 
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1H), 2.18 (dt, J = 14.0, 7.5 Hz, 4H), 2.11 – 1.96 (m, 3H), 1.85 (d, J = 14.3 Hz, 2H), 
1.78 – 1.44 (m, 12H), 1.45 – 1.34 (m, 2H), 1.31 – 1.07 (m, 9H), 0.91 – 0.63 (m, 
12H). Expected MW: 875.5, Found M+Na+: 898.67.   
 
4-((3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-(3,3-dimethyl-2-
oxopentanoyl)piperidine-2-carbonyl)oxy)propyl)phenyl)amino)-4-oxobutanoic acid 
(4) 
To a solution of SLF (3) (50 mg, 0.095 mmol, 1eq., Cayman Chemical) in 
dichloromethane, succinic anhydride (28.6 mg, 0.285 mmol, 3 eq., Sigma) and 
DIEA (12.3 mg, 0.095 mmol, 1 eq., Sigma) were added and stirred overnight. After 
reaction, solvents were removed and purified by HPLC (48mg, 96% yield). 1H NMR 
(400 MHz, DMSO) δ 12.16 (s, 1H), 10.07 (d, 1H), 7.80 – 7.01 (m, 4H), 6.89 (dd, J 
= 8.3, 1.3 Hz, 1H), 6.84 – 6.78 (m, 1H), 6.72 (dd, J = 8.1, 2.0 Hz, 1H), 5.67 (dd, J 
= 8.7, 5.0 Hz, 1H), 5.19 (dd, J = 13.1, 5.5 Hz, 1H), 3.76 (s, 3H), 3.75 (s, 3H), 3.62 
(s, 1H), 3.3 (s, 1H), 3.27 – 3.08 (m, 1H), 2.67 – 2.56 (m, 4H), 2.25 (d, J = 13.8 Hz, 
1H), 2.12 (d, J = 51.0 Hz, 2H), 1.79 – 1.56 (m, 5H), 1.44 – 1.29 (m, 1H), 1.26 (d, J 
= 13.0 Hz, 1H), 1.21 (s, 3H), 1.17 (s, 3H), 1.08 (dd, J = 7.3, 4.8 Hz, 1H), 0.84 (td, 
J = 7.5, 1.0 Hz, 3H). Expected MW: 624.30, Found M+H+: 625.41. 
 
N-((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-
methoxybenzenesulfonamide (8) 
The core of amprenavir was purified as previously described.[19] (i) 
(2S,3S)-1,2-Epoxy-3-(Boc-amino)-4-phenylbutane (5) (1 g, 3.8 mmol, 1 eq., 
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Sigma) was dissolved in isopropanol followed by dropwise addition of 
isobutylamine (1.39 g, 19 mmol, 5 eq., Sigma) and stirred overnight. Isopropanol 
was removed and the crude mixture was brought up in dichloromethane, washed 
with ddH2O and brine, dried over Na2SO4 and the solvent evaporated. Crude 
product was recrystallized in 1:1 Ethyl Acetate:Hexanes as a white solid (6) (930 
mg, 72.7%). (ii) Without further purification, (6) was dissolved in 1:1 
dichloromethane:water, chilled on ice and cesium carbonate was added. 4-
methoxybenzene sulfonyl chloride (627 mg, 3.03 mmol, 1.1 eq, Sigma) was 
dissolved in 5 mL dichloromethane and added dropwise over 1 hour and the 
reaction was stirred until completion as monitored by TLC. After reaction, the 
product was extracted with a large volume of dichloromethane and purified by 
column chromatography (25:75 EtOAc:Hexanes) as a white, waxy solid (7) (1259 
mg, 90%). (iii) The final amprenavir core (8) was deprotected in 50% TFA/DCM, 
monitored until completion by TLC and solvents were removed under vacuum to 
afford a yellow oily solid (quantitative yield). 1H NMR (400 MHz, DMSO) δ 7.85 (d, 
J = 5.4 Hz, 3H), 7.73 – 7.65 (m, 2H), 7.39 – 7.24 (m, 5H), 7.28 – 7.03 (m, 3H), 5.61 
(s, 1H), 3.97 (s, 1H), 3.83 (s, 3H), 3.32 (dd, J = 14.7, 5.6 Hz, 1H), 3.02 (dd, J = 
14.3, 5.4 Hz, 1H), 2.90 (dd, J = 13.7, 8.6 Hz, 1H), 2.84 – 2.61 (m, 3H), 1.86 (tt, J = 
12.9, 6.7 Hz, 1H), 0.80 (d, J = 6.5 Hz, 3H), 0.74 (d, J = 6.6 Hz, 3H). 
 
General synthetic scheme for bifunctional compounds (9a-f, 10a-f) 
A routine amine-coupling strategy was employed in all cases to synthesize 
diverse linkers to the amprenavir core. Boc- or Fmoc-protected amino acids 
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(0.246mmol, 1eq.) were dissolved in anhydrous DMF, followed by addition of 
HATU (103mg, 0.27mmol, 1.1eq.) and DIEA (38.1mg, 0.29mmol, 1.2eq.) under 
nitrogen. The mixture was allowed to stir for 30 minutes, after which time a solution 
of (8) (100mg, 0.246mmol, 1eq.) was added dropwise and allowed to stir overnight. 
After reaction, the crude product was brought up in dichloromethane, washed once 
with ddH2O and once with brine, dried with Na2SO4 and solvents were removed. 
The Boc or Fmoc protecting groups were removed with 50% TFA/DCM or 30% 4-
methylpiperdine/DMF, respectively. After deprotection, solvents were removed 
and each amino acid-amprenavir derivative was purified by HPLC. (Yield 50-80%) 
To a solution of 2 or 4 in anhydrous DMF (0.011mmol, 1eq.) was added 
HATU (5mg, 0.013mmol, 1.3eq.) and DIEA (3.7mg, 0.029mmol, 2.5eq.) under 
nitrogen and stirred for 30 minutes. A solution of amino acid-amprenavir derivative 
(0.011mmol, 1eq.) was added dropwise and stirred overnight in nitrogen 
atmosphere. The reaction was brought up in dichloromethane, washed once with 
brine and purified by HPLC to afford the final bifunctional molecules in modest yield 
(30-50%). After pooling fractions, purified compounds were run again by HPLC to 
ensure purity, which was conservatively estimated as peak area to baseline with 
should omitted. 
 
(S)-tetrahydrofuran-3-yl-((2S,3R)-3-hydroxy-4-((N-isobutyl-4-
methoxyphenyl)sulfonamido)-1-phenylbutan-2-yl)carbamate (11) 
A solution of (S)-(+)3-hydroxytetrahydrofuran (100mg, 1.13mmol, 1eq) was 
prepared in dichloromethane followed by addition of disuccinimidyl carbonate 
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(436mg, 1.70mmol, 1.5eq.) and DIEA (292mg, 2.26mmol, 2 eq.) and stirred until 
completion by TLC. To this solution of mixed carbonate, amprenavir core (5; 0.5eq) 
was added and the reaction was stirred overnight. Solvent was removed and the 
product was purified twice by HPLC. Expected MW: 520.22, Found M+H+: 521.16.  
 
2-(4-((4-((3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-(3,3-dimethyl-2-
oxopentanoyl)piperidine-2-carbonyl)oxy)propyl)phenyl)amino)-4-
oxobutanamido)methyl)-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (12) 
To a solution of 2 (6.2 mg, 0.010 mmol, 1eq.) was added HATU (4.7 mg, 0.013 
mmol, 1.3 eq.) and DIEA (3.9 mg, 0.030 mmol, 3eq.) in anhydrous DMF. The 
mixture was stirred for 30 minutes and a solution of 4’-(aminomethyl)-fluorescein 
(4.4 mg, 0.011mmol, 1.1eq.) was added dropwise. The crude product was purified 
by HPLC (4.5 mg, 46% yield). Expected MW: 967.39, Found M+H+: 968.61. 
 
2.6 Notes 
This chapter represents a portion of the work published in “Dunyak, B.M., 
Nakamura, R.L., Frankel, A.D. & Gestwicki, J.E. Selective Targeting of Cells via 
Bispecific Molecules That Exploit Coexpression of Two Intracellular Proteins. ACS 
Chem Biol 10, 2441-7 (2015).” Bryan M. Dunyak and Jason E. Gestwicki designed 
the experiments and synthetic schemes. Bryan M. Dunyak performed the 
experiments. 
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2.7 Appendix 
Full molecular structure and characterization of bifunctional compounds used in 
Chapters 2 and 3. 
 
Compound 9a: 
 
Expected MW: 1334.72, Found M+H+: 1335.90. Minimum purity 97.5%. 
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Compound 9b: 
 
Expected MW: 1334.72, Found M+H+: 1335.80. Minimum purity 85.5%. 
 
Compound 9c: 
 
Expected MW: 1410.75, Found M+H+: 1411.87. Minimum purity 85.6%. 
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Compound 9d: 
 
Expected MW: 1360.74, Found M+2H+: 1362.71. Minimum purity 91.5%. 
 
 
Compound 9e: 
 
Expected MW: 1414.75, Found M+H+: 1415.90. Minimum purity 92.3 %. 
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Compound 9f: 
 
Expected MW: 1491.83, Found M+H+: 1492.93. Minimum purity 95.1%. 
 
Compound 10a: 
 
Expected MW: 1083.52, Found M+H+: 1084.61. Minimum purity 95.5%. 
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Compound 10b: 
 
Expected MW: 1083.52, Found M+H+: 1084.64. Minimum purity 94.6%. 
 
 
Compound 10c: 
 
Expected MW: 1159.56, Found M+H+: 1160.64. Minimum purity 89.1%. 
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Compound 10d: 
 
Expected MW: 1109.54, Found M+H+: 1110.64. Minimum purity 98.0%. 
 
 
Compound 10e: 
 
Expected MW: 1163.55, Found M+H+: 1164.64. Minimum purity 83.0%. 
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Compound 10e: 
 
Expected MW: 1163.55, Found M+H+: 1164.64. Minimum purity 83.0%. 
 
 
Compound 10f: 
 
Expected MW: 1240.63, Found M+H+: 1241.71. Minimum purity 87.0%. 
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Chapter 3  
Selective Targeting of Cells that Exploit Coexpression of Two 
Intracellular Proteins 
 
3.1 Abstract 
In Chapter 2, I developed a small library of bifunctional molecules composed of an 
FKBP ligand and HIV protease inhibitor. These molecules were designed to 
provide a way of systematically varying the affinity for both protein targets. Next, 
we characterized our library in vitro to show that, as designed, these bifunctional 
molecules bind both FKBP12 and HIV protease with a range of affinities. In this 
Chapter, we explore whether bifunctional molecules might be capable of cyto-
selective targeting. Each of the compounds retained passive membrane diffusion 
and the best molecules inhibited FKBP12 and HIV protease activity in cells. Most 
excitingly, the molecules with tight affinity for FKBP12 and HIV protease were 
selectively taken up into cells that express both proteins. Treatment with 
competitive FKBP12 inhibitors partially blocked the partitioning of the compounds, 
while overexpression of FKBP12 enhanced it. Together, our data suggests that 
bifunctional molecules selectively accumulate in cells that express high levels of 
both protein partners and that this activity is driven by avidity effects. This result 
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has implications on the design of synthetic, bifunctional molecules, such as those 
that are nearing clinical trials. Further, these results suggest that the natural 
products, FK506 and rapamycin, might exploit this mechanism to gain potent 
pharmacological activity.  
 
3.2 Introduction 
3.2.1 Model for Selectively Targeting Cells via Intracellular Proteins 
Bi-specific antibodies offer the advantage of high selectively. Can bi-specific small 
molecules share this feature (Figure 3.1)? In part, we chose the HIV protease and 
FKBP12 model system because HIV infection commonly occurs in lymphocytes. 
As mentioned in Chapter 1, lymphocytes are a major tissue target of FK506,[1] 
 
Figure 3.1) Bifunctional molecules are cyto-selective and accumulate in cells highly 
expressing both protein targets. Molecules possessing high affinity for both FKBP12 
and HIV protease accumulate in cells that express both proteins in mixed cell 
populations. 
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likely because of the unusually high concentration of FKBP12 in these cells.[2] 
Thus, we envisioned that the selectivity of HIV protease inhibitors might be 
improved by directing them to the relevant cell population – cells expressing both 
HIV protease and FKBP12. Such a strategy might improve activity by 
concentrating the active molecule into the relevant cell subpopulation, which in this 
case would be HIV-infected lymphocytes.  
 
 
3.2.2 Enhanced Pharmacology of a Bifunctional HIV Protease Inhibitor 
As mentioned in Chapter 2, HIV protease inhibitors are clinically effective but 
poorly cell penetrant and rapidly metabolized.[3] Their efficacy is often limited by 
low intracellular concentration, which may allow for rapid accumulation of 
resistance-conferring mutations.[4] To address these shortcomings, our group 
previously developed a bifunctional HIV protease inhibitor based on SLF and the 
amprenavir core as a proof of concept that intracellular FKBP targeting may be 
successful (Figure 3.2).[5] Specifically, this molecule was designed to test whether 
sequestering an HIV protease inhibitor in blood cells might partially protect it from 
 
Figure 3.2) SLFavir is a first generation bifunctional HIV protease inhibitor with 
enhanced pharmacological properties. Anti-protease activity is retained in vitro and 
SLFavir is able to effectively partition into cells. 
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metabolism and extend its half-life in vivo. Like other SLF-based CIDs, a short 
linker was appended off the phenyl motif and coupled to amprenavir. The 
compound (SLFavir) retained anti-HIV protease activity in vitro and was 
investigated for in vivo efficacy.  
 
Blood samples taken from mice treated with SLFavir were fractionated into cellular 
or plasma components and analyzed for whole drug content by LC-MS. While the 
parent amprenavir compound was found to be equally sequestered in cellular and 
plasma fractions, SLFavir accumulated into the cellular compartment (Figure 
3.3A), consistent with their design. Recovery and extraction of the HIV protease 
 
Figure 3.3) SLFavir preferentially accumulates in the cellular compartment, enhancing 
local drug concentration and improving efficacy. A) SLFavir primarily partitions into the 
cellular compartment, unlike the parent Amprenavir. B) Accumulation in the cellular 
compartment protects SLFavir from rapid first pass metabolism. C) SLFavir is more 
effective than the unmodified Amprenavir core in a model of live virus HIV infection. 
This is attributed to enhanced permeability and cellular accumulation of SLFavir. 
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inhibitor followed by determination of in vitro anti-protease activity suggested that 
SLFavir was protected from metabolism and degradation, unlike the parent 
amprenavir compound (Figure 3.3B). Using a cell model for HIV infectivity with live 
virus in CEM T lymphocytes, SLFavir was tested against unmodified amprenavir 
core and found to be approximately 80-fold more potent at preventing virion 
replication and subsequent infection (Figure 3.3C). Together, these studies show 
that FKBP12 binding can be used to “hide” a bifunctional HIV protease inhibitor to 
improve its poor pharmacological properties. However, the underlying mechanism 
for this improvement was unknown. Put another way, it wasn’t clear how this 
activity might be “tuned” to increase accumulation of the HIV protease inhibitor in 
blood cells. This feature is important because eventual clinical use of such 
molecules may require adjusting lifetime and potency. For my thesis project, I 
wanted to understand the properties governing this effect and show whether 
bifunctional HIV protease inhibitors might be selectively targeted to relevant cell 
populations. 
 
3.3 Results 
3.3.1 Bifunctional Molecules Retain Passive Membrane Permeability 
Before progressing into cellular models, we first explored the membrane 
permeability of the compounds using a standard parallel artificial membrane 
permeability assay (PAMPA). PAMPA assays are routinely used to quickly 
measure membrane permeability of drugs for a first approximation of 
bioavailability.[6] In this case, we used a newly-designed lipid-oil-lipid tri-layer 
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system that is able to more accurately predict membrane permeability of non-
canonical small molecules like our bifunctional library. Compound is added to a 
“donor well”, then a filter plate containing buffer alone is added. After incubation, 
compound concentration is quantified on each side of the membrane (Figure 
3.4).Consistent with their large size, the bifunctional molecules exhibited modest 
passive diffusion rates (1-2x10-6 cm/s, Figure 3.5). In comparison, the permeability 
 
Figure 3.4) Design of artificial permeability assay. Compound is placed in a donor well 
and allowed to passively permeate into the acceptor wells. Depending on the 
compound composition, different permeability constants can be measured (illustrated 
as red to gray arrows). 
 
Figure 3.5) Artificial membrane permeability of the bifunctional library. In comparison 
to control compounds, the bifunctional molecules retained modest permeability despite 
their size. Results are the average of at least three independent experiments performed 
in triplicate. Error bars are SEM. 
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rates for FK506 (3.2x10-6 cm/s) and amprenavir (4.8x10-6 cm/s) are considered 
fairly low, with the standard control compound acyclovir being impermeable. Thus, 
the permeability values of the bifunctional molecules are only 2- to 5-fold less than 
the parent compounds, suggesting that the modifications had relatively modest 
effects on permeability. With these baselines established, we added recombinant 
human FKBP12 to one side of the PAMPA membrane and measured the 
partitioning of a subset of compounds. Ideally, FKBP12 binding would sequester 
free compound on one side of the membrane, acting as a sink for free drug in 
solution, driving the equilibrium towards enhanced permeability. As we anticipated, 
FKBP12 enhanced partitioning by 2- to 5-fold compared to control wells (Figure 
3.6), providing proof-of-concept that protein binding could retain the molecule on 
 
Figure 3.6) Addition of FKBP12 enhances partitioning of the bifunctional molecules but 
not Amprenavir. Recombinant FKBP12 added to the acceptor well sequesters 
compounds containing a FKBP-binding moiety. This effect is not observed with 
Amprenavir, which does not have FKBP-binding activity. Results are the average of at 
least three independent experiments performed in triplicate. Error bars are SEM. 
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one side of a membrane. Additionally, the partitioning of amprenavir – which is not 
able to bind to FKBPs - was unaffected by FKBP12. We desired to see if HIV 
protease could enhance partitioning in a similar fashion, but found that the buffers 
tolerated in the PAMPA system were not compatible with HIV protease solubility. 
Thus, we turned to a cellular assay. 
 
3.3.2 Design of a Cell-Based GFP-HIV Protease Reporter System 
To measure HIV protease binding in cells, we adapted an assay that uses a GFP-
HIV protease reporter (Figure 3.7).[7, 8] This method relies on the observation that 
expression of HIV protease culminates in rapid cytotoxicity and cell death in 
mammalian cells.[9, 10] In this system, active HIV protease first cleaves GFP 
before cell death occurs, thus GFP stability is a proxy for anti-HIV protease activity. 
When a protease inhibitor is added, the cells become fluorescent and are able to 
proliferate. In this way, the extent of partitioning and HIV protease binding can be 
estimated from the stabilization of GFP and measured fluorescence levels. To 
further control the expression of the GFP-HIV protease fusion construct, we 
 
Figure 3.7) Cell-based reporter system for HIV protease inhibition using a GFP-HIV 
protease fusion protein. Inhibition of HIV protease stabilizes GFP fluoresence and 
rescues cell viability. Lack of inhibition of HIV protease results in cytotoxicty and cell 
death. 
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generated stable HEK293 T-REx cell lines under the control of a Tet repressor. 
This cell system has been developed to stably incorporate a gene of interest at a 
known flippase recombination target (FRT) site. Transient transfection of the 
pCDNA5 vector containing the gene of interest alongside Flp recombinase allows 
for intermolecular DNA recombination at the FRT site. Successful integration 
incorporates a Hygromycin B resistance cassette, and monoclonal populations can 
be selected. Since expression of the GFP-HIV protease fusion construct is closely 
regulated by the Tet repressor, little background expression occurs and cell 
viability is not impacted.  
 
3.3.3 Protease Inhibitors Stabilize the GFP-HIV Protease Reporter 
 
Figure 3.8) Protease inhibitors stabilize GFP fluorescence, but FK506 does not. 
Doxycyclin induces expression of the GFP-HIV protease fusion construct, which is 
stabilized by inhibition via HIV protease inhibitor. The FK506 control does not inhibit 
the active HIV protease and stablize GFP fluorescence, which ultimately leads to cell 
death as seen in the brightfield image. 
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Using fluorescence microscopy, we found that HIV protease was auto-proteolyzed 
following doxycycline induction in the absence of HIV protease inhibitor, leading to 
cell death (Figure 3.8). However, treatment with amprenavir or 9a (5 µM), but not 
FK506 or DMSO, could rescue cell viability and increase fluorescence, as 
observed by fluorescence and brightfield microscopy. To validate these findings, 
we used western blots to examine protein expression levels (Figure 3.9). After 
induction with doxycycline, we saw robust expression of the GFP-HIV fusion 
 
Figure 3.9) GFP-HIV protease is abundantly expressed and stabilized by the addition 
of protease inhibitor. Both 9a and 10a lead to some degradation of the GFP-HIV 
protease construct, while the control Amprenavir does not. Both FK506 and DMSO 
allow for the active protease to cleave GFP in to a smaller, inactive form, ultimately 
leading to cell death. 
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construct. Treatment with 9a, 10a and amprenavir stabilized the full fusion protein, 
while DMSO and FK506 did not. Interestingly, we saw some slight degradation of 
the GFP-HIV protease fusion construct with 9a, but not with amprenavir. This 
suggested that the bifunctional molecules were less effective than amprenavir to 
stabilize the GFP-HIV protease fusion construct. However, amprenavir is a highly 
optimized drug that has reached regulatory approval and includes addition of the 
tetrahydrofuranyl urethane group where we install the linker of our molecules. This 
group dramatically enhances affinity for HIV protease, and amprenavir is 
approximately 10-fold higher affinity than the most effective bifunctional molecule 
in our library. Therefore, we were pleased to see that our compounds were nearly 
as effective as the approved drug. We next desired to analyze our library using a 
higher-throughput, more quantitative approach. To do so, we measured the effects 
of compounds 9a-f and 10a-f on GFP expression by flow cytometry. Populations 
of cells were gated and the median fluorescence of each population was analyzed 
(Figure 3.10A). Titrating compound shows a shift in the fluorescent population with 
a decrease in the median fluorescence intensity, which could then be quantified to 
 
Figure 3.10) Flow cytometry analysis of fluorescent GFP-HIV protease cells. A) 
Treatment with protease inhibitor results in two populations of cells, one with high 
fluorescence intensity in the FITC channel and one without fluorescence. Each 
population of cells is gated and the median fluorescence (red dotted line) of the high 
intensity population is quantified. B) Titration of compound shifts the median of the high 
intensity fluorescent population. 
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determine EC50 values for each compound (Figure 3.10B). These studies showed 
that the best compounds, such as compounds 9a-c or 10a-c, also had potent anti-
protease activity in the cells. Satisfyingly, the most potent molecules from this 
experiment were also those with the best anti-protease activity in the biochemical 
assays. For example, compound 9a was significantly better than 9f (Figure 3.11). 
We also noticed that there was an apparent “activity cliff” in the results. In other 
words, compounds 9a-c were active in the GFP-HIV protease assay, while 9d-f 
were largely inactive rather than simply weaker. This type of threshold response 
has been observed previously for HIV protease inhibitors and is likely due to an 
inability to stabilize the active site.[11] The second observation from our studies 
was that compounds 9a-c, bearing the FK506 group, were significantly more 
potent than the equivalent compounds with the SLF moiety, 10a-c (all IC50 > 5000 
nM). These results suggest that the affinity for FKBP is critical to cellular 
partitioning. FKBP12 is more abundantly expressed (concentration estimated to 
 
Figure 3.11) Quantification of anti-HIV protease activity using the cell-based GFP 
reporter. FK506-based bifunctional molecules exhibited higher activity against the 
GFP-HIV protease reporter, despite relatively similar permeability. Some compounds 
with low activity against HIV protease had no efficacy in this assay. Results are the 
average of at least three experiments in which fluorescence from 10,000 cells per 
concentration were quantified. Error bars were calculated from the three independent 
experiments. 
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be high micromolar)[12] than HIV protease, consistent with FKBP12 being a major 
determinant of compound retention in the cytosol.  
 
3.3.4 FKBP12 Drives Partitioning of the Bifunctional Molecules 
These results suggested that the availability of FKBP12 may tune partitioning. As 
a test of this idea, we saturated available FKBP12 sites using free FK506 or SLF 
as direct competitors and tested the efficacy of 9a. Competitive ligand modestly 
reduced fluorescence in the GFP-HIV reporter cells, with FK506 being more potent 
than the weaker binding SLF (Figure 3.12). This is to be expected, as 9a is based 
on FK506 and is significantly more potent than SLF. To test this idea in the 
opposite direction, we increased the available pool of FKBP12 through transient 
overexpression of an mCherry-FKBP12 construct (Figure 3.13). After the 
transfected cells were allowed to recover, we treated with 9a and used microscopy 
 
Figure 3.12) Competition of intracellular FKBP binding sites with FK506 reduces 
efficacy of the bifunctional molecule 1a. Pre-treatment with the high-affinity competitive 
ligand FK506, but not SLF, is capable of reducing the anti-HIV protease activity of 
FK506 derivative 9a. Results are the average of at least three experiments in which 
fluorescence from 10,000 cells per concentration were quantified. Error bars were 
calculated from the three independent experiments. 
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to reveal that GFP fluorescence was concomitantly increased in cells that also had 
high levels of mCherry-FKBP12 (merge, Figure 3.13). Amprenavir did not show 
this dependence on mCherry-FKBP12 expression, showing that bivalency was 
required. To ensure the mCherry-FKBP12 construct was being over-expressed, 
we analyzed treated cells by Western blot. As in Figure 3.9, we saw that protease 
inhibitor stabilized the GFP-HIV protease fusion protein. However, the additional 
expression of mCherry-FKBP12 enhanced the activity of both 9a and 10a (Figure 
3.14, lanes 1 and 2), emphasized by the reduction of cleaved GFP in the anti-GFP 
blot. Under these conditions, the activity of 9a was enhanced to the level of the 
control Amprenavir. Using flow cytometry, we then quantified the effect of FKBP12 
on partitioning. Specifically, we isolated the subpopulation of cells (approximately 
50%) that had high levels of mCherry expression. In these cells, the EC50 for 9a 
 
Figure 3.13) GFP-HIVp stabilization is enhanced in 9a treated mCherry-FKBP12 cells. 
Cells expressing increased FKBP12 had higher coincident stabilization of GFP-HIV 
protease in 9a treated cells but not in cells treated with Amprenavir (merge). 
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was substantially improved (Figure 3.15A, EC50 = 600 nM in the FKBP12low cells 
vs. EC50 = 105 nM in the FKBP12high cells). Interestingly, cells negative for 
mCherry-FKBP12 in this experiment had apparent EC50 values that were slightly 
worse than cells that were never transfected (~ 380 nM vs 600 nM). We interpret 
this result as being consistent with the FKBP12 over-expressing cells acting as a 
sink for compound 9a, reducing its availability for other cells. Co-treatment with 
free FK506 reversed the enhanced partitioning effect in the over-expressing 
FKBP12 cells (Figure 3.15B), demonstrating that it is indeed due to the availability 
of FKBP12. Consistent with our model, overexpression of FKBP12 had no effect 
 
Figure 3.14) Overexpression of FKBP12 enhances activity of the bifunctional HIV 
protease inhibitors. Both 9a and 10a had reduced levels of GFP cleavage, suggesting 
increased activity of the compounds via enhanced partitioning. 
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on the partitioning of the control 11 (Figure 3.16A) and the IC50 was unchanged 
(Figure 3.16B). Finally, we performed live virus HIV-infectivity assays. Consistent 
with our cell-based reporter assay, we observed that 9a was significantly more 
 
Figure 3.15) Partitioning of 9a is “tuned” by the levels of free FKBP12.A) Shift in dose-
response curves are dependent on the available FKBP12 for binding. B) Quantification 
of the ability of FKBP12 to tune partitioning, as judged by flow cytometry. Results are 
the average of at least three experiments in which fluorescence from 10,000 cells per 
concentration were quantified. Error bars were calculated from the three independent 
experiments. Statistical analysis was conducted using a one-way ANOVA (p < 0.001) 
and posthoc Dunnett’s multiple comparisons test with 1a as a reference (*p < 0.05, 
***p < 0.001). 
 
Figure 3.16) Overexpression of FKBP12 does not enhance the partitioning of 11. A) 
Increasing the available FKBP12 for binding has no effect on the ability of 11 to stabilize 
GFP in the GFP-HIVp cells. B) Quantification of the ability of FKBP12 to tune 
partitioning, as judged by flow cytometry. Results are the average of two experiments 
in which fluorescence from 10,000 cells per concentration were quantified. Error bars 
are SD. Statistical analysis was conducted using a one-way ANOVA (not significant). 
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potent than 10a (Figure 3.17), further supporting the idea that the affinity for FKBP 
determines relative partitioning. Together, these results show that bi-specific 
molecules take advantage of dual expression of two proteins to gain enhanced 
cyto-selectivity. These results are summarized in Table 3.1. 
 
3.4 Discussion 
 
Figure 3.17) Affinity for each bivalent interaction mediates cellular anti-infectivity 
activity of bifunctional molecules. Viral replication is inhibited by 9a and 10a 6 and 8 
days post-infection. 9a exhibits greater efficacy due to the tighter affinity for FKBP12 
despite identical protease inhibitor motifs. Infectivity curves are representative of 
experiments performed twice in triplicate. Error bars are SD. 
 
Table 3.1) Quantification of cell-based activity assays. Values are the IC50 in nM. 
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The selectivity of a drug for its target cell in an animal helps determine its maximum 
safe dose by limiting damage to bystander cells. Using in vitro permeability assays, 
we found that the bi-specific molecules retained permeability despite their 
increased size and were sequestered on one side of a membrane by FKBP12. 
This partitioning partially overcame the poor permeability of the molecules, 
emphasizing that target engagement impacts equilibrium across membranes.[13] 
Then, using a modified version of a cell-based GFP reporter assay, we confirmed 
that interactions with FKBP12 and HIV protease also control partitioning in cells. 
Binding to FKBP12 dominated the cyto-selectivity effect, likely because it 
represents a greater pool of available binding sites. To further explore the role of 
FKBP12, we used pharmacological competitors and overexpression to 
systematically control the number of free binding sites. Consistent with a key role 
for this binding partner, overexpression of an mCherry-FKBP12 construct could 
further enhance partitioning (and anti-HIV protease activity), while competitors 
neutralized this effect. These results suggest that the key design principles in 
engineering cyto-selective small molecules are the abundance of the protein 
partners and the avidity of the interactions, reminiscent of what has been found for 
bi-specific antibodies  
 
This concept is supported by the results of the live viral assays, in which compound 
9a was found to be much more potent than 10a. However, we anticipate that this 
strategy may be beneficial in other situations in which therapeutics need to be 
guided to a specific cell type with precision. For example, many transformed cells 
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express high levels of at least two possible targets, such as oncoproteins, cell cycle 
proteins and molecular chaperones. Using bi-specific molecules might enhance 
selectivity for these cancer cells and reduce accumulation in healthy cells. Also, 
recent work has established ways of degrading target proteins, including FKBP12, 
by recruiting the cereblon E3 ligase.[14-16] Alternatively, this approach may be 
beneficial for the optimization of “cocktail” therapies, where multiple drugs are 
given to simultaneously target a particular disease. This is most common in 
HAART for HIV, in which four or five different drugs may be given in combination. 
This is necessary to ensure optimal inhibition of HIV replication, since targeting 
multiple drugs to the infected cells can be a challenge with low systemic 
accumulation.  Using a bifunctional approach may be another strategy for delivery 
of two drugs to the same cell, guaranteeing a high local concentration of both 
therapeutics. The results presented here might inform ways of thinking about how 
these bi-specific molecules might take advantage of dual binding to generate cyto-
selectivity. 
 
3.5 Methods 
3.5.1 Plasmid Generation and Protein Purification 
For cell-based studies, FKBP12 was cloned into the pcDNA3 mCherry ligation 
independent cloning vector (Fwd: 5’-TAC TTC CAA TCC AAT GCC ACC ATG 
GGA GTG CAG GTG GAA ACC AT CT CC-3’, Rev: 5’-CTC CCA CTA CCA ATG 
CCT TCC AGT TTT AGA AGC TCC ACA TCG AAG-3’). The GFP-HIV protease 
fusion construct was originally purchased from Addgene (#20253) and subcloned 
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into the pcDNA5/FRT/TO vector with BamHI/XhoI restriction sites (Fwd: 5’- ATAG 
GAT CCA TGG TGA GCA AGG GCG AGG AGC T-3’, Rev: 5’- CTT ACT CGA 
GTT AGG CCG CCA GTG TGA TGG A-3’).  
 
3.5.2 Parallel Artificial Membrane Permeability Assay 
Assay plates were purchased from Corning and stored at -30 °C until use. Plates 
were returned to room temperature and equilibrated for at least 30 minutes before 
opening. An acceptor well solution was prepared consisting of PBS (Gibco) and 
5% DMSO. Compounds were diluted to 400 μM in DMSO and then added to PBS 
1:20 to a final concentration of 20 μM. This initial solution was measured for UV 
absorbance at 280 nM and then added to the donor well of the PAMPA plate in 
triplicate. The acceptor plate containing the phospholipid membrane was slowly 
added into the donor plate and acceptor well solution was added. Plates were 
incubated at room temperature for 5 hours at room temperature before 100 μL 
aliquots were taken from both the donor and acceptor wells and analyzed by UV 
absorption to determine passive diffusion across the membrane. Permeability was 
calculated as follows: 
𝑃𝑒 =  
−ln (1 − 𝐶𝐴/𝐶𝑒𝑞)
𝑆 ∗ (
1
𝑉𝐷
+
1
𝑉𝐴
) ∗ 𝑡
        𝐶𝑒𝑞 =
𝐶𝐷 ∗ 𝑉𝐷 − 𝐶𝐴 ∗ 𝑉𝐴
𝑉𝐷 − 𝑉𝐴
 
and, 
𝐶𝐷 =  𝐶0 ∗
𝐴𝐷 − 𝐴𝑏𝑢𝑓𝑓𝑒𝑟
𝐴0 − 𝐴𝑏𝑢𝑓𝑓𝑒𝑟
       𝐶𝐴 =  𝐶0 ∗
𝐴𝐴 − 𝐴𝑏𝑢𝑓𝑓𝑒𝑟
𝐴0 − 𝐴𝑏𝑢𝑓𝑓𝑒𝑟
 
where Pe = permeability (cm/s), CA = acceptor well final concentration, CD = donor 
well final concentration, Ceq = equilibrium concentration, S = membrane surface 
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area, t = incubation time (seconds), VD = donor well volume, VA = acceptor well 
volume and A0,A,D,buffer = absorbance for initial solution absorbance, acceptor well 
final absorbance, donor well final absorbance and buffer background absorbance, 
respectively. 
 
3.5.3 Generation of GFP-HIV Protease Cell Lines 
HEK293 T-REx cells were grown in DMEM supplemented with 10% FBS at 37 °C 
in 5% CO2. pcDNA5/FRT/TO containing the GFP-HIV protease fusion was 
transiently transfected into cells with different ratios of pOG44 (Invitrogen) with 
Lipofectamine 3000. Clones incorporating GFP-HIVp at the FRT site were selected 
with Hygromycin B (Roche) then checked for Zeocin sensitivity and expression 
levels after doxycyclin induction via fluorescent microscopy.  
 
3.5.5 Transient Expression of mCherry-FKBP12 
HEK293 T-Rex cells were transiently transfected with an mCherry-FKBP12 
pcDNA3 expression plasmid. Expression levels were qualitatively analyzed by 
fluorescence microscopy. Media was replaced 12 hr after transfection and cells 
were grown for an additional 24 hours before plating for GFP-HIV Protease 
induction and compound treatment. 
 
3.5.6 Flow Cytometry Analysis of Fluorescent Construct Expression 
HEK293 cells incorporating the GFP-HIVp fusion construct were plated at 20,000 
cells/well in clear 96-well TC-treated plates and grown for 24 hours. Compounds 
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were titrated down in DMSO, diluted to 5X final concentration with PBS and 10 μL 
was added to each well to a final volume of 200 μL and 1% DMSO. Doxycyclin 
was then added to each well at 1 μg/ml to induce GFP-HIVp expression. Cells 
were incubated for 36 hours at 37 °C in 5% CO2, media aspirated, washed once 
with PBS and trypsinized. Cells were then re-suspended in ice-cold PBS and 
analyzed on a BD LSRii cytometer for GFP fluorescence. Median fluorescence for 
each well was determined. To analyze FKBP12 levels, cells positive for mCherry 
fluorescence were gated and median GFP fluorescence was measured. 
 
3.5.7 Western Blot Analysis 
Treated cells were washed twice with cold PBS and lysed with RIPA buffer at 4 °C 
for 30 minutes. Cell lysate was centrifuged for 25 min at 15,000 xg to pellet 
insoluble material and supernatant was collected. A BCA was performed and 
concentrations were corrected with RIPA buffer such that 2.5 micrograms total 
protein was loaded per well. SDS-PAGE was performed and the proteins 
transferred to nitrocellulose membrane, followed by subsequent washing and 
immunoblotting. Antibodies were obtained from Santa Cruz Biotechnology and 
detected with Amersham ECL Detection Kit. 
 
3.6 Notes 
This chapter represents a portion of the work published in “Dunyak, B.M., 
Nakamura, R.L., Frankel, A.D. & Gestwicki, J.E. Selective Targeting of Cells via 
Bispecific Molecules That Exploit Coexpression of Two Intracellular Proteins. ACS 
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Chem Biol 10, 2441-7 (2015).” Figure 3.3 was adapted from previous work by Paul 
S. Marinec. Bryan M. Dunyak and Jason E. Gestwicki designed the experiments 
and synthetic schemes. Bryan M. Dunyak performed the experiments, with the 
exception of the live virus anti-HIV infectivity assay performed by Robert L. 
Nakamura and Alan D. Frankel in Figure 3.17. 
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Chapter 4  
Novel Design of Inhibitors Targeting the PPIase Pin1 
 
4.1 Abstract 
Pin1 is unique among the PPIases because it only binds to prolines that directly 
follow phosphorylated serine or threonine residues (pS/T-P motif). This activity is 
important as the phosphate of the pS/T-P motif sterically hinders the local peptide 
backbone and dramatically slows the spontaneous cis-trans isomerization of the 
proline. Thus, Pin1 activity becomes essential for isomerization of this motif on a 
relevant physiological time scale. Moreover, Pin1’s clients include multiple cell 
cycle regulators, modulators of stress responses, and transcription factors. In 
these clients, isomerization of pS/T-P motifs is used as an essential regulatory 
switch, often in tandem with proline-directed kinases. Accordingly, misregulation 
or overexpression of Pin1 is implicated in numerous diseases, including cancer 
and neurodegeneration, making Pin1 an especially attractive target. However, as 
introduced in Chapter 1, attempts to discover Pin1 inhibitors have had limited 
success. The requirement for a highly electronegative group in the Pin1 active site, 
mimicking the pS/T-P interaction, seems to render many potential inhibitors 
inactive in cell and animal models because of poor permeability. In this chapter, 
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our hypothesis is that the excellent pharmacological properties of FK506 might 
make it a suitable chemical scaffold for engineering Pin1 inhibitors. We reasoned 
that these molecules might take advantage of the mechanisms outlined in 
Chapters 1, 2, and 3, to yield potent, selective and long-lived inhibitors. However, 
FK506 itself has little affinity for Pin1, because it lacks the key, electronegative 
region essential for Pin1 binding. To overcome this hurdle, we have designed a 
novel semisynthetic strategy to modify FK506 at a position likely to improve affinity 
and selectivity for Pin1. We found that installing a sulfamic acid at the C10-position 
of the macrocyclic ring significantly improved the affinity for Pin1 (>100-fold) in 
vitro. This molecule is designed to yield the first high-affinity membrane-permeable 
inhibitors of Pin1, which should prove to be a powerful chemical probe of this 
PPIase. 
 
4.2 Introduction 
4.2.1 Pin1 Plays a Diverse Role in Cellular Homeostasis 
Pin1 has a unique role among all of the PPIases in that it only recognizes prolines 
immediately following phosphorylated serine or threonine residues (known as the 
pS/T-P motif).[1] This unique feature of Pin1 bindings is mediated by a cationic 
groove formed by Lys-63, Arg-68 and Arg-69, which makes contact with the pS/T 
group (Figure 4.1).[2] In turn, isomerization of bound substrate is thought to be 
mediated by the nearby residue Cys-113.[3] Like other PPIases, Pin1 also has a 
hydrophobic “shelf” adjacent to the proline pocket that it uses to gain additional 
contacts (see Chapter 1). 
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In addition to its PPIase domain, Pin1 has an N-terminal WW domain, that seems 
to contribute to the binding of phosphopeptide substrates. The WW domain does 
not possess intrinsic isomerase activity, and the reason for overlapping substrate 
preference with the PPIase domain is unclear. It is thought that the WW domain 
may initially localize with relevant clients, but the hand-off mechanism to the 
PPIase domain for isomerization is unknown.  
 
Pin1 and its orthologs have been discovered in all eukaryotes and they are known 
to be critical for cell cycle regulation and cellular homeostasis. In Saccharomyces 
cerevisiae, the Pin1 homolog Ess1 is essential,[4] and complementation with 
 
Figure 4.1) Structure of Pin1 with key features highlighted. A) Ribbon diagram. The 
active site pocket within the PPIase domain is composed of antiparallel β-strands that 
position a short α-helix. The WW domain consists of two, short antiparallel β-strands 
connected to the PPIase domain by a flexible linker (not resolved in this structure). B) 
Surface representation of the active site. The hydrophobic proline pocket (gray) orients 
substrate to interact with the catalytic cysteine (yellow) and the cationic groove that 
binds phosphate groups (blue). (PDB: 1PIN) 
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human Pin1 rescues viability.[1] One essential activity of Pin1 is in regulation of 
the cell cycle, through its activity on numerous phosphorylation-dependent 
regulatory pathways. Pin1 works in tandem with ‘proline-directed’ kinases and 
phosphatases, binding and isomerizing the peptide backbone of the pS/T-P motifs 
to alter the prolyl cis/trans conformation. This is especially important in the context 
of pS/T-P motifs, as they have been shown to isomerize 8-fold slower than their 
non-phosphorylated counterparts.[5] This slow rate is driven by specific contacts 
between the phosphate moiety and the amide backbone.[6] Since proline 
isomerization already represents a significant bottleneck in protein dynamics 
phosphoprotein substrates of Pin1 require the specific isomerase activity of this 
chaperone to function. Pin1-mediated conformational changes have been 
implicated in activating transcription factors, facilitating dephosphorylation or 
degradation of clients, stabilizing protein-protein interactions and targeting proteins 
for specific subcellular localization.[7]  
 
4.2.1 The Role of Pin1 in Disease 
The importance of Pin1 for cellular homeostasis and the progression through 
mitosis suggests that misregulation of this protein may lead to a variety of disease 
states. Indeed, Pin1 has been implicated in both cancer and neurodedgeneration. 
Pin1 interacts with multiple oncogenes, such as p53, and often enhances their 
oncogenic activity. Significant Pin1 overexpression has been found in numerous 
cancer types, including prostate, brain, breast, ovary, cervical and melanomas.[8] 
Conversely, low Pin1 expression has been correlated to increased neuronal 
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vulnerability and enhanced degeneration of neurons and neurofibrillary tangle 
formation during AD-like pathologies.[9] Pin1 is often sequestered into paired 
helical filaments (PHF) of hyperphosphorylated tau[10] while soluble Pin1 is 
deactivated by oxidative stress at its catalytic cysteine.[11] Thus, Pin1 expression 
and activity is often inversely correlated with disease; it is upregulated and highly 
active in cancer, or downregulated and inactive in neurodegenerative 
diseases.[12] For these reasons, Pin1 inhibitors are of significant interest as 
potential anti-cancer therapeutics, where modulation of Pin1 levels have been 
shown to be effective at preventing tumorigenesis. Further, Pin1 inhibition may 
have some therapeutic benefit in certain neurodegenerative diseases, such as in 
tauopathies where specific destabilizing mutations in tau have exhibited a 
decrease in pathogenesis when Pin1 levels are reduced.[13] 
 
4.2.2 Natural Product Inhibitors of Pin1 
Finding high affinity, cell permeable inhibitors has been an active and ongoing 
pursuit for many years.[14] Discovered as the first Pin1 inhibitor, Juglone (Figure 
4.2) functions by covalent modification of Cys-113 in the active site.[15] Juglone is 
 
Figure 4.2) Natural product inhibitors of Pin1. 
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produced by the Black Walnut tree and its inhibition of Pin1 activity has been 
suggested to contribute to the toxicity of Black Walnuts. However, the exact 
binding interaction of Juglone is unclear and this compound has proven to have 
other cellular targets, possibly acting non-specifically.[16] To date, no inhibitors are 
known to mimic this mode of inhibition. Interestingly, Juglone does not inhibit the 
FKBPs or cyclophilins, whereas Pin1 has not been shown to have any appreciable 
affinity for the natural products, rapamycin, FK506 or cyclosporin. This observation 
is perhaps surprising, due to the similarity between active sites across the 
PPIases. However, Pin1 is unique among the PPIases because of its phospho-
peptide binding activity through a positively charged surface. Thus, Pin1 inhibitors 
must navigate this feature of the pocket by including highly electronegative 
substituents. The challenge is that these same features often reduce membrane 
permeability. Other natural product derivatives (Figure 4.2) have been shown to 
inhibit Pin1 while also engaging the phosphate-binding region, providing an 
alternate approach towards novel scaffolds. Dexamethasone-21-phosphate is a 
synthetic corticosteroid prodrug found to modestly inhibits Pin1 activity (KD = 
2.2uM).[17] By NMR and X-ray crystallography, dexamethasone-21-phosphate 
was shown to bind across the proline pocket to the cationic groove formed by Lys-
63, Arg-68 and Arg-69. Using a similar screening strategy, the vitamin A derivative 
all-trans retinoic acid (ATRA)  was found to be a submicromolar inhibitor of Pin1 
(KD = 0.8uM) and bound similarly to dexamethasone-21-phosphate.[18] The 
cyclohexene ring is anchored into the proline binding pocket with the alkene chain 
extending the carboxylic acid into the cationic phosphate-binding region. 
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Treatment with ATRA suppresses proliferation of mouse embryonic fribroblasts 
and leads to Pin1 degradation but has no effect in Pin1 knockout cells or those 
harboring inactivating mutations in the binding site. In a model of acute 
promyelocytic leukemia (APL), ATRA facilitates degradation of the fusion 
oncoprotein promyelocytic leukemia-retinoic acid receptor α (PML-RAR-α)  and 
was shown to be due to the inhibition of the stabilizing effect of Pin1. This was 
further demonstrated in a breast cancer model where Pin1 is highly expressed and 
possesses pro-oncogenic activity. Inhibition of Pin1 by ATRA limited tumorigenicity 
of MDA-MBA-231 cells injected into mice in a dose-dependent manner. Inhibitors 
based on these natural products may be a promising starting point. 
  
4.2.3 Peptidomimetics Demonstrate the Necessity for Charged Substituents in 
Pin1 Inhibitors 
Because of the challenges with the Pin1 site, early inhibitors were primarily based 
on peptides. Although these molecules haven’t been useful as probes in cells or 
 
Figure 4.3) Representative pipecolic acid-based phosphopeptide inhibitor of Pin1. The 
phosphopeptide, pintide, is bound to Pin1 (shown as the surface electrostatic map). 
Significantly, the pipecolate ring is anchored in the proline binding pocket, positioning 
the phosphate group to interact with the cationic groove (blue). Further affinity is gained 
via the napthyl interaction with the hydrophobic shelf of the active site. 
91 
 
animals, they have illustrated the features of the active site. In one approach, a 
combinatorial library of 5-mer N-acetylated peptides incorporating unnatural amino 
acids surrounding a phosphothreonine residue was screened against the PPIase 
domain of Pin1. The strongest hit contained a pipecolate core not unlike those 
found to strongly inhibit FKBPs that is central to the binding region of FK506 and 
rapamycin. Optimization of the peptide resulted in “pintide” (Ac-Phe-D-Thr(PO3H2)-
Pip-Nal-Gln-NH2; Figure 4.3), which had a Ki ≈ 18 nM. Switching the 
phosphothreonine residue to the L-isomer (*) resulted in a 30-fold loss in activity 
(Ki ≈ 550 nM) and removing the phosphate group ablated the interaction. Addition 
of the WW domain in the full-length protein did not alter binding preference, which 
was perhaps unexpected due to the overlapping substrate specificity of the two 
domains.[19] Crystallization of the L- and D-peptide versions of pintide yielded 
surprising results, with nearly identical conformations of the stereoisomers. In both 
structures, the electronegative phosphate group was anchored into the phosphate 
recognition pocket, contacting Lys-63 and Arg-69. The pipecolate core rested in 
the proline-binding pocket, making hydrophobic contacts with Leu-122, Met-130 
and Phe-134. The naphthylalanine side chain extends up and stacks on a 
hydrophobic shelf formed by Leu-122 and the top of the Met-130 side chain.[20] 
Based on these structures, the reasons for the large difference in binding affinity 
are not obvious. Strikingly, the Pin1 active site occupied by these peptides adopted 
a conformation that is reminiscent of FKBP when bound to rapamycin, with both 
pipecolic rings in nearly identical orientations. However, rapamycin has no 
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measureable affinity for Pin1 so the affinity of the peptides for Pin1 must originate 
through the phosphate-binding surface. 
 
4.2.4 Early Design of Small Molecule Pin1 Inhibitors 
Guided by the Pin1 crystal structure, FKBP ligands were modeled in the Pin1 
active site to design novel small molecules. The first compound was found to be a 
low micromolar inhibitor (Ki ≈ 1.7 µM), which was promising for a de novo lead 
(Figure 4.4). Attempts to optimize the charge by replacing the phosphate with a 
sulfate resulted in a significant drop in potency (9.5 µM). Re-installing the 
phosphate and appending a propylbenzene to the carbinol center improved 
potency to 0.8 µM and inhibited cell cycle progression of CA46 cells at 15 µM 
(4.4a). However, these compounds were not ligand efficient, so the scaffold was 
abandoned. The pipecolyl ester found in FK506 and rapamycin was replaced with 
a phenylalaninol phosphate as the minimum binding epitope. A pilot chemical 
screen identified a bi-aryl amide scaffold, which inhibited Pin at 100 nM (Figure 
4.5). Derivatization and co-crystallization of (4.5a) revealed a new binding pose, 
with the compound rotated to allow the phenyl group to dock into the hydrophobic 
 
Figure 4.4) Small molecule Pin1 inhibitors based on pipecolic acid. Note the 
resemblance to FKBP inhibitors, such as SLF.  
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proline pocket and placing the benzothiophene on the hydrophobic shelf formed 
by Leu-122 and Met-130.[21] The phosphate group was rotated slightly and bound 
in-between Arg-68 and Arg-69, losing the interaction with Lys-63 as in the previous 
phosphopeptide inhibitors. This suggests that there is some flexibility in orienting 
the phosphate group in these compounds, with the positive charge being spread 
throughout a large region of the active site. However, this series of compounds 
were inactive in whole cell assays, likely due to the poor permeability of the 
phosphate group. Subsequent derivatization to replace the phosphate group with 
either a primary alcohol or carboxylic acid (Figure 4.6) resulted in a significant drop 
in potency; the alcohol inactivated the compound while the carboxylate retained 
weak Pin1 inhibitory activity (4.6a, Ki ≈ 28 µM). This was deemed suitable and the 
carboxylate-based scaffold was the subject of a limited SAR series.[22] In addition 
to modifications of the phenyl ring system, phosphate bioisosteres, such as 
tetrazoles, acylaminothiazols and acylsulfonamides, were tried in replacement of 
the carboxylic acid. Unfortunately, only the tetrazole retained the same activity as 
 
Figure 4.5) Bi-aryl amides potently bind Pin1.Bi-aryl amides potently bind Pin1. Co-
crystallization with 65c (PDB: 3IKG) revealed a new binding orientation with the phenyl 
ring oriented in the proline-binding pocket and the phosphate group oriented between 
Arg-68 and Arg-69. (PDB: 3IKG) 
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the carboxylate. It was hypothesized that export by P-glycoprotein efflux pumps 
may be responsible for the limited activity of this series. The amidyl carboxylate 
moiety in particular was implicated in recognition by P-glycoprotein, and it was 
concluded that further optimization of the scaffold was necessary to achieve 
cellular activity. 
 
In an alternate approach, engagement of peripheral residues flanking the cationic 
phosphate-binding region was shown to be effective in the development of Pin1 
 
Figure 4.7) Alternative bi-aryl scaffold engages peripheral residues of the Pin1 cationic 
groove. Spanning the phosphate-binding region (Lys-63, Arg-68, Arg-69) enhances 
affinity for Pin1, even without engagement of the hydrophobic shelf. 
 
Figure 4.6) Optimization of the bi-aryl amide scaffold to enhance cellular permeability. 
The phosphate group was replaced with a carboxylic acid, which retained a similar 
binding pose as (4.5a) with the orientation of the carboxylate facing Lys-63 as in the 
phosphopeptide inhibitors. (PDB: 4TYO) 
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inhibitors (Figure 4.7). An initial fragment-based screen was performed to inhibit 
Pin1 isomerase activity on a model substrate and confirmed in a follow-up NMR 
platform.[23] Optimization of the primary hit (4.7a) resulted in a phenyl-imidazole 
fragment substituted at the 3-position (4.7b; Figure 4.7), a site shown previously 
to be effective in engaging the proline pocket. Unfortunately, these compounds 
also lacked cellular activity. Subsequent modification of the central imidazole ring 
resulted in a series of amide substituted 3-chloro-phenyl-imidazole inhibitors with 
modest affinity for Pin1 (4.7c, IC50 ≈ 2.0 µM)  that were cell penetrant and able to 
inhibit cell division and Pin1-mediated cyclin D1 expression at micromolar levels. 
Furthermore, these compounds had a unique binding mode in Pin1, flanking Lys-
63, Arg-68 and Arg-69 in the phosphate recognition pocket. It is worth noting that 
these fragments do not engage the hydrophobic shelf, as seen with other potent 
Pin1 inhibitors (4.5a, 4.5b).  
 
Together, these small molecules are the first Pin1 inhibitors that possess cellular 
activity. Yet, cellular activity is relatively low, especially compared to the high 
affinity observed in the Pin1 in vitro assays. Attempting to optimize permeability by 
using phosphate bioisosteres has been unsuccessful.  Furthermore, these 
compounds have not yet been shown to be effective in animal models. Critical to 
the design of these small molecules, they all engage the cationic phosphate-
binding site. Additional affinity is gained from either interacting with the 
hydrophobic shelf or residues adjacent to the phosphate binding site. In general, 
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all of these compounds suffer from an inability to adequately partition and 
sequester into cells. 
 
4.2.5 Remodeling FK506 and Rapamycin for Anti-Pin1 Activity 
In Chapter 2 and 3, we showed that FK506 effectively drives the partitioning of HIV 
protease inhibitors into relevant cells. We wondered if a similar strategy may 
overcome the major problems that have plagued discovery of Pin1 inhibitors. As 
discussed above, early investigation into Pin1 inhibitors involved modifying the 
core scaffold of FKBP ligands based on the pipecolate core, which resulted in a 
series of compounds with good affinity. However, these molecules still suffered 
 
Figure 4.8) Overlay of the bound conformation of FK506 compared to the pintide 
phosphopeptide, highlighting the potential modification site. A) Aligning the pipecolate 
ring in FK506 to the pintide phosphopeptide demonstrates the binding pose similarity of 
each compound and proximity to the cationic phosphate binding site. B) FK506 and 
Rapamycin shown with the FKBP binding motif highlighted in red. The tertiary hydroxyl 
is highlighted (Yellow arrow in A, third panel. Black arrow in B). 
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from poor permeability. So, we wondered if the favorable properties of FK506 could 
be leveraged to drive the permeability of analogs containing electronegative 
groups.   
 
To design an initial model, I created an overlay of the Pin1 active site with bound 
FK506 and compared it to the known co-crystal structures of Pin1 with inhibitors 
containing a pipecolate core. Analysis of these structures suggested that FK506 
analogs might bind to Pin1 if the cationic groove could be sufficiently occupied 
(Figure 4.8). Likewise, modified analogs of rapamycin were predicted to have a 
similar interaction. 
 
Analyzing the structure of both FK506 and Rapamycin highlighted the tertiary 
hydroxyl as being a potential point for modification. Unfortunately, initial attempts 
to derivatize the macrocycles at this position were not successful, likely due to the 
lack of reactivity of the hydroxyl. During our initial investigations into the feasibility 
of engineering Pin1-specific FK506/rapamycin derivatives, we rediscovered an 
obscure report on modifying the natural products at this position.[24] Specifically, 
the authors showed that treatment of either of these macrocycles with methanolic 
ammonia converts the tertiary hydroxyl into a primary amine by an undetermined 
mechanism (Figure 4.9). We predicted that the primary amine substitution at this 
position would create an orthogonally reactive handle for further derivatization. 
However, we first wanted to systematically explore the chemistry of this reaction, 
as it had remained underexplored. 
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4.3 Results 
4.3.1 Semisynthetic Modification of FK506 and Rapamycin 
Using the previously reported conditions, FK506 was treated with methanolic 
ammonia (2M) and monitored by HPLC (Figure 4.10). Within 30 minutes, we saw 
conversion of FK506 into a more polar product (13, herein FK-NH2), which we 
attributed to the primary amine. At the same time, we noticed that the unreacted 
FK506 peak appeared to develop a slightly more polar shoulder and that a small 
number of minor side products were produced. It had previously been suggested 
 
Figure 4.9) Semisynthetic modification of FK506 and rapamycin. Straightforward 
modification of the tertiary hydroxyl of FK506 and Rapamycin into a primary amine for 
further derivatization. 
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that treatment of FK506 with ammonia could also result in formation of the imine 
at the adjacent carbonyl, so we hypothesize that the “shoulder” might be the less 
polar imine. However, we have not been able to isolate enough of this compound 
for an in-depth characterization by NMR and MS. Similarly, we reasoned that the 
excess ammonia could be modifying FK506 with both the amine and imine, which 
 
Figure 4.10) Conversion of FK506 into FK-NH2. Within 30 minutes, a significant portion 
of FK506 is converted into the amine-containing derivative. 
 
Figure 4.11) Reaction rate of the FK506 conversion. Data was fit to a one-phase 
exponential. 
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would explain the other trace product slightly more polar than the FK-NH2 peak. 
With these caveats, we quantified the HPLC traces to determine the amount of 
product formation and fit the data to a first order exponential (Figure 4.11). We only 
observed approximately 60% product formation, largely owning to the off-pathway 
side products. At longer time points, we did not see the reaction continue but 
FK-NH2: 
 
FK506: 
 
Figure 4.12) Comparison of FK-NH2 and FK506 by MS. In the converted FK-NH2, the 
parent amine is readily ionized unlike in FK506. 
101 
 
instead saw significant degradation of both FK506 and the putative amine 
derivative.  
 
Next, we characterized the presumed FK-NH2 product by MS and NMR. The 
molecular mass was readily observed by MS (Figure 4.12. M+H+: 803.63, 
expected: 803.50), which is in contrast to the parent compound FK506. This 
represents a slight decrease in mass (~ 1 amu) compared to FK506. However, the 
imine would also exhibit the same mass loss, so we turned to NMR. Due to the 
complexity of the compound and the large number of hydrogens (70 in FK-NH2), 
we opted for 13C NMR. Guided by previous peak assignments, we observed that 
 
Figure 4.13) Downfield region of the FK-NH2 13C NMR spectrum. The C10 peak 
corresponding to the tertiary hydroxyl attachment point is typically at 97ppm (yellow 
highlight), but appears shifted after conversion to the amine (green highlight). 
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the C10 peak was significantly shifted (Figure 4.13).[25] Rather, this carbon was 
shifted upfield, consistent with attachment of an amine.  Interestingly, we observed 
a slight double peak in the shifted spectrum, possibly due to tautomerization of 
FK506 in this region of the molecule. We are currently pursuing small molecule X-
ray crystallography to further confirm the structure and its absolute stereochemistry 
as we continue the conversion of FK-NH2 to desired products. 
 
4.3.2 Solvent Screen of the FK506 Substitution Reaction 
During scale-up of FK-NH2, we noticed that preparative HPLC purification of the 
converted product led to reversion to FK506. We suspected that this 
decomposition may be due to the acidic mobile phase used (0.1% TFA in 
H2O/ACN), so we decided to pursue a one-pot approach to carry forwards the FK-
NH2 without purification. First, we attempted to optimize the concentration of 
ammonia to improve yield and minimize residual starting material in subsequent 
reactions. This led to a characteristic change in the observed peak shapes that 
 
Figure 4.14) Determination of concentration effects on the conversion of FK506. HPLC 
traces are shown of the reaction after two hours in various concentrations of ammonia 
without and with peak highlighting (left and right, respectively). Increasing ammonia 
concentration seems to result in formation of a new species that is less polar than FK-
NH2. 
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progressed as concentration was increased (Figure 4.14). At 1M ammonia, little 
reaction was observed that consisted of primarily unreacted FK506 and only a 
small amount of the FK-NH2 product forming (box 1). The 2M reaction progressed 
as normal, with increased formation of FK-NH2 (box 1) and appearance of the 
imine “shoulder” (box 3) that overlapped with the FK506 peak. Higher 
concentration 3.5M ammonia largely converted FK506 (box 4) with a mixture of 
FK-NH2 (box 1) and a previously not seen side product (box 2). Likewise, 7M 
ammonia produced only the new peak (box 2), with no FK-NH2 formation 
occurring. We suspect that the high concentration of ammonia causes some form 
of off-pathway rearrangement, possibly opening of the lactone after the initial 
formation of the converted FK-NH2. MS analysis of the products was inconclusive. 
 
Using the 2M ammonia conditions, we proceeded to optimize solvent conditions. 
For these experiments, we chose a series of solvents to represent a range of 
properties from polar (DMPU) to nonpolar (DCM), as well as protic (methanol) to 
aprotic (DMPU, dioxane, DCM) solvents. Notably, to this point we were performing 
the reactions by first diluting a stock 7M ammonia in methanol solution, which is 
commercially available, to a final concentration of 2M. For the solvent screens we 
used the same strategy, which resulted in a solvent mixture consisting of the co-
solvent plus residual methanol as a by-product of the dilution. Surprisingly, none 
of the solvent mixtures supported conversion to FK-NH2, even at longer reaction 
times (Figure 4.15). This result suggested that solvent effects were critical to the 
reaction. Because of the reasonable effectiveness of methanol, we next focused 
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on an additional series of alcohols. Interestingly, all of the alcohols supported 
conversion to FK-NH2, with ethanol being slightly preferred (Figure 4.15). 
Performing the reaction in trifluoroethanol did not lead to significant conversion, 
 
Figure 4.15) Solvent dramatically effects the conversion of FK506. Alcohols are heavily 
preferred in the conversion of FK506, with other polar and protic solvents leading to 
only minimal product formation after three hours.  
 
Figure 4.16) Deuterated methanol slightly enhances the rate of reaction. 
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which we hypothesized could be due to the lower pKa of the free hydroxyl 
compared to ethanol (12.5 versus 15.9, respectively). Consistent for the role of the 
hydroxyl pKa, the reaction progressed slightly faster in methan(ol-d). From these 
optimization studies, we selected ethanol with 2M ammonia (75% yield) for 
subsequent experiments. 
 
4.3.3 Investigating the Reactivity of amino-FK506 and amino-Rapamycin 
Our first attempts at derivatization of FK-NH2 involved a simple alkylation of the 
amine using 3-chlorobenzyl bromide (product 15; Figure 4.17). Unfortunately, the 
yield was very low, with optimization of the reaction resulting in approximately 10% 
product formation. In part, we chose to begin with the 3-chlorobenzyl bromide 
reagent because we feared that modification of the amine would be difficult and 
the 3-chlorobenzene group would act as a fingerprint. By 1H NMR the 3-
chlorobenzene ring was easily visible, as neither FK506 nor FK-NH2 have any 
aromatic protons, and the chlorine isotopic signature was observed by MS. This 
confirmed that the desired product was formed, albeit in low yield. 
 
Figure 4.17) Semisynthetic scheme to derivatize FK-NH2. (i) 2M ammonia, ethanol. (ii) 
FK-NH2, 3-chlorobenzyl bromide (3eq), DIEA (6 eq), DMAP (0.1eq), DCM. 
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To test the scope of the reaction, we performed alkylations with benzyl 
(compounds 16 and 17), alkyl (compounds 21 and 22) and carboxyl-containing 
groups (compounds 18-20; Table 4.1). However, we were only able to achieve low 
or trace product formation. Increasing temperature or reactant equivalents typically 
resulted in FK-NH2 degradation before reaction occurred. Increasing the leaving 
group propensity was likewise ineffective, with only low yield observed with the 
tosylate (compound 22).  
 
Based on these results, we explored amide formation as an alternative 
(compounds 23-26; Table 4.2). However, traditional amide coupling techniques 
(DIC/DIEA/DMAP) did not produce significant product. Even the use of HATU, a 
highly reactive coupling agent designed for peptide synthesis, was not sufficient 
for these reactions. However, some conversion was observed with the p-
nitrophenol ester, a highly activated amide formation reagent that may be viable in 
future reactions.  
 
Thus, we moved to progressively more reactive amide coupling conditions (Table 
4.3). In neat acetic anhydride FK-NH2 proceeded to the desired product (27) in 
quantitative yield. Next, a series of other anhydrides were attempted. Initial 
attempts with succinic anhydride (28) were frustrated by addition of multiple 
succinates, but optimization of reaction conditions allowed for reduction in the 
number of equivalents that afforded the desired compound. Similar profiles were 
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Compound 
ID 
Reactant Desired Product Yield 
Attempted 
Conditions 
15 
 
 
12% a,b,h 
16 
 
 
10% a,b,e,f,g 
17 
 
 
trace d,e,f 
18 
 
 
25% a,b,h 
19 
 
 
N/A a,g 
20 
 
 
N/A a 
21 
 
 
N/A a,c,e,h 
22 
 
 
5% a,b,d,e,f,g 
 
aDMF, DIEA 
bDCM, DIEA, DMAP 
cTHF, DIEA 
dToluene, DIEA 
eDMF, Pyridine 
fDMF, DIEA, DMAP, 50°C 
gDCM, DIEA, DMAP, 50°C 
hDMF, Cs2CO3 
Table 4.1) Attempted alkylations and conditions of FK-NH2. The pyranose fragment is 
shown where modification occurs. Yield is approximate as determined by product 
appearance in MS compared to residual starting material. 
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observed with anhydride reactions yielding 29 and 31. The one outlier was 
observed with trifluoroacetic anhydride (30), which did not yield any product. We 
are actively pursuing 31, as installation of a reactive electrophile would be an 
additional strategy to append a variety of substituents to the molecule to create 
potential Pin1 inhibitors. Finally, a small series of acid chlorides are being explored 
as an alternate to the anhydrides. Neither 32 nor 33 resulted in sufficient product 
formation, but reaction conditions are continuing to be optimized. Lastly, the 
Compound 
ID 
Reactant Desired Product Yield 
Attempted 
Conditions 
23 
 
 
N/A a,b 
24 
 
 
5% a,b,c,d,e 
25 
 
 
trace d,e 
26 
  
N/A d,e 
 
aDMF, DIEA, DMAP 
bDCM, DIEA, DMAP 
cDMF, Pyridine 
dDMF, DIEA, DMAP, 50°C 
eDCM, DIEA, DMAP, 50° 
fDMF, DIEA, HATU 
 
Table 4.2) Attempted amide formations and conditions of FK-NH2. The pyranose 
fragment is shown where modification occurs. Yield is approximate as determined by 
product appearance in MS compared to residual starting material. 
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Compound 
ID 
Reactant Desired Product Yield 
Attempted 
Conditions 
27 
 
 
100% a,e,f 
28  
 
100% b,c,d,e,f 
29 
 
 
100% b,c,e,f 
30 
 
 
N/A f 
31 
 
 
100% f 
32 
 
 
trace f 
33 
 
 
N/A d,e,f 
34 
 
 
25% c,d 
 
aNeat 
bDMF, DIEA 
cDCM, DIEA 
dDCM, DIEA, DMAP 
eDMF, DIEA, 50°C 
fDCM, DIEA, DMAP, 50°C 
Table 4.3) FK-NH2 amide formation using anhydrides and acyl chlorides. The 
pyranose fragment is shown where modification occurs. Yield is approximate as 
determined by product appearance in MS compared to residual starting material. 
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reaction to produce 34 was chosen in an attempt to synthesize the sulfamic acid 
as a direct phosphate bioisostere and proceeded in low to modest yield (~25%). 
Further attempts to characterize this compound are underway.  
 
In summary, a series of FK-NH2 derivatives have been prepared in modest yields. 
Reactions in nonpolar conditions seem to be heavily favored and the anhydrides 
were significantly more reactive than other approaches. This synthetic route 
provides an entry into FK506 analogs designed to bind Pin1 
 
4.3.4 Binding of FK506 Derivatives to FKBP12 and Pin1 by Fluorescence 
Polarization 
To test binding to Pin1, we chose to employ a fluorescence polarization assay. 
This assay was based on our FP approach to measure binding to FKBP12 from 
Chapter 2. We found that a fluorescein-tagged substrate (WFYpSPFLE) bound 
with tight affinity to wild-type Pin1 (KD = 10.1 ± 4.1 nM, Figure 4.18A), which was 
in good agreement with the known phosphopeptide substrates. Binding to the 
PPIase domain was considerably weaker (KD = 427 ± 98 nM), although not 
unexpected, as the WW domain is known to contribute to binding. Purified 
compounds were titrated in a competition format against static tracer and Pin1 
protein. Only one compound appeared to be active in this format, the sulfamic acid 
34, which possessed sub-micromolar activity for the wild-type construct (KiWT = 
931nM, KiPPIase = 4350nM, Figure 4.1B). This was promising, as this compound 
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would be most likely to engage the Pin1 cationic groove via electrostatic 
interactions with the charged sulfonate moiety.  
 
Next, we tested the effects of our modification on FKBP12 binding. Based on the 
known FK506 binding interaction, we would expect many of these derivatives to 
have significantly impaired affinity for FKBP12. To test this, we used the FKBP12 
binding assay (Chapter 2) to measure Ki values for the new FK506 analogs (Figure 
4.19). We found that small alkyl substitutions, such as in 19, were reasonably well 
tolerated. Larger functional groups (such as in compounds 15 and 24) resulted in 
a significant drop in affinity, as expected. Lastly, the sulfamic acid substitution in 
34 had nearly a 500-fold loss of potency. This result is encouraging, it shows that 
Pin1 binding can be favored at the expense of FKBP12 binding. 
 
 
Figure 4.18) The phosphopeptide WFYpSPFLE binds to Pin1 and is competed by 34. 
A) Wild-type Pin1 and the PPIase domain (see B legend) bind with good affinity to the 
phosphopeptide tracer. The smaller PPIase domain has a lower ∆mP corresponding to 
its smaller molecular mass. B) The phosphopeptide tracer is competed by 34, which 
contains an electronegative sulfamic acid group that likely engages the Pin1 cationic 
groove. Experiments are the average of at least two experiments with duplicate 
measurements. Error is SEM. 
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4.4 Discussion 
As discussed in Chapter 1, the discovery of effective, cell-permeable Pin1 
inhibitors has remained a significant challenge. In this Chapter, we first discussed 
numerous strategies that have been designed to identify Pin1 inhibitors. The 
requirement for a strongly electronegative group typically precludes membrane 
permeability of these molecules, limiting their use. Some improvement has been 
made for small molecules where the phosphate group is substituted by a carboxylic 
acid, but the cellular activity of these ligands is weak. Other strategies, such as 
phosphate prodrugs and bioisosteres, have also been unsuccessful.  
 
In my thesis work, I was inspired by the natural mechanisms of FK506 and 
rapamycin (Chapter 1). Despite their high molecular mass and chemical 
complexity, they possess excellent pharmacological properties, specifically 
membrane permeability. Early studies on bifunctional molecules (Chapter 2 and 3) 
took advantage of this trait, and our investigation into this mechanism found that 
 
Figure 4.19) Competitive binding to FKBP12 of our FK506 derivatives. A) Modification 
of FK506 at this position dramatically reduces affinity for FKBP12 depending on the 
functional group properties. B) Ki calculations of the FK506 derivatives in comparison 
to FK506. Results are the average of triplicates and error is SEM. 
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appending a PPIase ligand to HIV protease inhibitors could significantly improve 
its cellular partitioning (Chapter 2). Here, I wanted to see if these features could be 
exploited to create potent Pin1 inhibitors. The early small molecules of Pin1 were 
based on the pipecolate scaffold found in FK506 and rapamycin, suggesting that 
the core recognition motif might be conserved. In addition, I found that the bound 
conformation of pipecolate-containing Pin1 inhibitors is highly reminiscent of 
FK506 bound to FKBP12 (Figure 4.8). Despite these similarities, FK506 has no 
measurable affinity for Pin1, likely because it lacks the electronegative functional 
group that is unique to Pin1 binding. We decided to pursue the semisynthetic 
modification of FK506 to impart Pin1 binding. We found that FK506 could be 
converted to FK-NH2 at a region that is predicted to be in close proximity to the 
phosphate-binding region of the Pin1 active site. Indeed, compound 34 had affinity 
for Pin1 in vitro with FKBP12 binding considerably reduced. We are currently 
exploring the permeability of these analogs and creating more potent versions, 
 
One of the goals of this study was to optimize the route for creation of FK-NH2. 
We found that the concentration of ammonia was critical; 1M ammonia resulted in 
the reaction stalling without significant conversion, while concentrations above 2M 
caused undesirable side-product formation. Dramatic solvent effects were also 
observed, with suitable conversion only occurring in alcohols. We found that FK-
NH2 would revert to FK506 during purification, so we moved to a one-pot strategy 
for subsequent derivatization. It was immediately apparent that the installed amine 
of FK-NH2 had limited reactivity, because direct alkylation with alkyl halides or 
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amide coupling with activated carboxylic acids or acyl chlorides was only 
moderately effective. However, we found that anhydrides allowed robust product 
formation in excellent yields (~100% in most cases). These systematic studies are 
expected to facilitate the creation of a larger collection of potential Pin1 inhibitors, 
with the next series of FK-NH2 derivatives bearing substituents designed for Pin1 
binding. 
 
In the next stage of this project, it will be essential to understand the binding 
interaction and cellular activity of these molecules. In collaboration with the Fraser 
lab, we are pursuing crystal structures of the free molecules as well as co-
crystallized with Pin1. Fortunately, Pin1 has been well validated as a target in a 
variety of cell lines, including its impact on cell viability in numerous human 
cancers, so we propose to use these established models to test the cellular activity 
of the molecules. 
 
4.5 Methods 
4.5.1 Plasmid Generation and Protein Purification 
Wild-type Pin1 was obtained from the lab of Dr. Dustin Maly in the pMCSG7 vector 
for bacterial expression and purification. The PPIase domain (45-163) of Pin1 was 
cloned into the pMCSG7 vector using ligation independent cloning (Fwd: 5’-TAC 
TTC CAA TCC AAT GCA AAA AAC GGG CAG G-3’, Rev: 5’-TTA TCC ACT TCC 
AAT GTT ACT CAG TGC GGA GGA TGA-3’) for bacterial expression and 
purification.  
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The Pin1 constructs were transformed into E. coli BL21(DE3) cells and grown in 
Terrific Broth for six hours at 37 °C, followed by induction with 1 mM IPTG at 20 
°C for 12 hours. Cells were collected, lysed by sonication (25 mM Tris, 500 mM 
NaCl, 10 mM imidazole, 10% glycerol, pH 8.0) and was bound on Ni-NTA resin. 
Resin was washed once with wash buffer 1 (25 mM Tris, 500 mM NaCl, 30 mM 
imidazole, 3% ethanol, 10% glycerol, pH 8.0), once with wash buffer 2 (25mM Tris, 
100mM NaCl, 30mM imidazole, 3% ethanol, 10% glycerol, pH 8.0), once with wash 
buffer 3 (25mM Tris, 300mM NaCl, 30mM imidazole, 10% glycerol, pH 8.0) and 
eluted (25 mM Tris, 300 mM NaCl, 300 mM Imidazole, 10% glycerol, pH 8.0). 
Eluted protein was dialyzed overnight (10mM HEPES, 100mM NaCl, 5% glycerol, 
pH 7.5) and purified by Size Exclusion Chromatography using a SD75 column with 
the dialysis buffer. 
 
4.5.2 Pin1 Fluorescence Polarization Assay 
Binding to Pin1 was measured by fluorescence polarization. The assay was 
performed at 60 μL final volume in MOPS (pH 7.5) with 0.01% Triton X-100 using 
Corning 384-well flat-bottom black plates. For initial binding analysis of the 
fluorescent compound, recombinant Pin1 was serially diluted 3-fold from 80 μM 
initial concentration and then 30 μL added to each well for a top concentration of 
40 μM. Fluorescent phosphopeptide WFYpSPFLE was initially dissolved in DMSO 
at 100 μM then dissolved into assay buffer and 30 μL of this solution was added 
to each well to give a final concentration of 75 nM. The plate was covered and 
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equilibrated at room temperature for 30 minutes then read on a SpectraMax M5 at 
wavelength 488/515 ex/em. 
 
Competition experiments were performed under similar conditions. Separate 
solutions of Pin1 and fluorescent peptide at were prepared and then 15 μL of both 
was added to each well. The final concentrations used in the assay were 50nM 
and 1000nM for wild-type Pin1 and the Pin1 PPIase domain, respectively. 
Compounds were initially dissolved in DMSO to 10 mM, serially diluted 2-fold, then 
diluted to 400 μM with assay buffer and 30 µL was added to each well to a final 
top concentration of 200 μM and 2% DMSO. The assay was equilibrated at room 
temperature for 30 minutes and then read as before. 
 
4.5.3 Synthetic Methods 
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4R)-4-
hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-1-amino-23,25-dimethoxy-14-
hydroxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-
azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone (13) 
 To a solution of FK506 (1) (25mg, 0.031mmol, 1eq) in 2.5mL ethanol was 
added 1mL 7M ammonia in methanol to a final concentration of 2M (excess). The 
reaction was allowed to stir for 3 hours before solvent and ammonia were removed 
by evaporation. The crude product was dried under high vacuum for 30 minutes to 
afford 13 as an oily, translucent solid (75% yield). Expected MW: 802.50, Found 
M+H+: 803.63.  
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(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4R)-4-
hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-1-((3-chlorobenzyl)amino)-23,25-
dimethoxy-14-hydroxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-
4-azatricyclo[22.3.1.0(4,9)]octacos-18-ene-2,3,10,16-tetrone (15) 
 To a solution of (13) (12.5mg, 0.016mmol, 1eq) in 2mL DCM was added 
DMAP (0.6mg, 0.005mmol, 0.3eq) and allowed to stir under N2. 3-chlorobenzyl 
bromide (9.9mg, 0.048mmol, 3eq) was added dropwise followed by the addition of 
DIEA (12.4mg, 0.096mmol, 6eq). After 24 hours, the solvent was removed by 
evaporation and the crude product dissolved in 1mL methanol and purified by 
HPLC (25% yield). Expected MW: 926.51, Found M+ACN+: 968.93. 
 
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4R)-4-
hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-1-benzylamino-23,25-dimethoxy-
14-hydroxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-
azatricyclo[22.3.1.0(4,9)]octacos-18-ene-2,3,10,16-tetrone (16) 
 To a solution of (13) (20mg, 0.025mmol, 1eq) in 2mL DMF was added 
DMAP (1.0mg, 0.008mmol, 0.3eq) and allowed to stir under N2. Benzyl bromide 
(42.8mg, 0.25mmol, 10eq) was added dropwise followed by the addition of DIEA 
(64.8mg, 0.5mmol, 20eq). The reaction temperature was raised to 50°C. After 24 
hours, the crude product was purified by HPLC (10% yield). Expected MW: 892.54, 
Found M+H+: 893.62. 
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(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4R)-4-
hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-1-((2-(tert-butoxy)-2-
oxoethyl)amino)-23,25-dimethoxy-14-hydroxy-13,19,21,27-tetramethyl-17-(prop-
2-en-1-yl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4,9)]octacos-18-ene-2,3,10,16-
tetrone (18) 
 To a solution of (13) (25mg, 0.031mmol, 1eq) in 2mL DCM was added 
DMAP (1.2mg, 0.010mmol, 0.3eq) and allowed to stir under N2. Tert-Butyl 
bromoacetate (18.1mg, 0.093mmol, 3eq) was added dropwise followed by the 
addition of DIEA (24.1mg, 0.186mmol, 6eq). After 24 hours, the solvent was 
removed by evaporation and the crude product dissolved in 1mL methanol and 
purified by HPLC (25% yield). Expected MW: 916.57, Found M+ACN+: 959.01. 
 
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4R)-4-
hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-1-((carboxymethyl)amino)-23,25-
dimethoxy-14-hydroxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-
4-azatricyclo[22.3.1.0(4,9)]octacos-18-ene-2,3,10,16-tetrone (19) 
 The protected derivative (18) (5mg, 0.005mmol, 1eq) was dissolved in a 
solution of DCM:TFA:TIPS:H2O (45:45:5:5) and stirred for 30 minutes. TIPS was 
included as a cation scavenger. Solvent was evaporated and the crude product 
was purified by HPLC (5% yield). Expected MW: 860.50, Found M+H+: 861.04. 
 
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4R)-4-
hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-1-ethylamino-14-
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hydroxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-
azatricyclo[22.3.1.0(4,9)]octacos-18-ene-2,3,10,16-tetrone (22) 
 To a solution of (13) (25mg, 0.031mmol, 1eq) in 2mL DMF was added 
DMAP (1.2mg, 0.010mmol, 0.3eq) and allowed to stir under N2. Ethyl p-
toluenesulfonate (124.2mg, 0.62mmol, 20eq) was added dropwise followed by the 
addition of DIEA (160.6mg, 1.24mmol, 40eq). The reaction temperature was raised 
to 50°C. After 24 hours, the crude product was purified by HPLC (5% yield). 
Expected MW: 830.53, Found M+Na+: 853.58. 
 
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4R)-4-
hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-1-(2-bromoacetamido)-23,25-
dimethoxy-14-hydroxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-
4-azatricyclo[22.3.1.0(4,9)]octacos-18-ene-2,3,10,16-tetrone (24) 
 To a solution of (13) (12.5mg, 0.016mmol, 1eq) in 2mL DMF was added 
DMAP (0.6mg, 0.005mmol, 0.3eq) and allowed to stir under N2. 4-Nitrophenyl 
bromoacetate (4.2mg, 0.016mmol, 1eq) was added dropwise followed by the 
addition of DIEA (6.2mg, 0.048mmol, 3eq). The reaction temperature was raised 
to 50°C. After 24 hours, the crude product was purified by HPLC (5% yield). 
Expected MW: 924.42, Found M+ACN+: 966.99. 
 
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4R)-4-
hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-1-acetamido-23,25-dimethoxy-14-
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hydroxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-
azatricyclo[22.3.1.0(4,9)]octacos-18-ene-2,3,10,16-tetrone (27) 
 To (13) (12.5mg, 0.016mmol, 1eq) was added 1mL neat acetic anhydride 
and stirred under N2. After 3 hours, the reaction was diluted with toluene and 
solvent was evaporated. This was repeated in total 3 times to remove as much 
unreacted acetic anhydride as possible. The crude product was dissolved in 
methanol and purified by HPLC (42% yield). Expected MW: 844.51, Found M+Na+: 
867.58. 
 
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-1-[(1R,3R,4R)-4-
hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-1-benzamido-23,25-dimethoxy-14-
hydroxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-
azatricyclo[22.3.1.0(4,9)]octacos-18-ene-2,3,10,16-tetrone (29) 
To a solution of (13) (12.5mg, 0.016mmol, 1eq) in 2mL DCM was added DMAP 
(0.6mg, 0.005mmol, 0.3eq) and allowed to stir under N2. Benzoic anhydride 
(18.1mg, 0.08mmol, 5eq) was added dropwise followed by the addition of DIEA 
(20.7mg, 0.16mmol, 10eq). After 24 hours, the solvent was removed, crude 
product was dissolved in 1mL methanol and purified by HPLC (10% yield). 
Expected MW: 924.42, Found M+ACN+: 966.99. 
 
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R) -12-[(1E)-1-[(1R,3R,4R)-
4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-14-hydroxy-1-
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sulfoamino-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-
azatricyclo[22.3.1.0(4,9)]octacos-18-ene-2,3,10,16-tetrone (34) 
To a solution of (13) (12.5mg, 0.016mmol, 1eq) in 2mL DCM was added DMAP 
(0.6mg, 0.005mmol, 0.3eq) and allowed to stir under N2. Chlorosulfonic acid 
(2.8mg, 0.024mmol, 1.5eq) was added dropwise followed by the addition of DIEA 
(20.7mg, 0.16mmol, 10eq). After 24 hours, the reaction had gone cloudy and 
solvent was removed. The crude product was dissolved in 1mL methanol and 
purified by HPLC (25% yield). Expected MW: 882.45, Found M-H+: 881.87. 
 
4.6 Notes 
This chapter represents a portion of the work published in “Dunyak, B.M. & 
Gestwicki, J.E. Peptidyl-Proline Isomerases (PPIases): Targets for Natural 
Products and Natural Product-Inspired Compounds. J. Med. Chem. In press. 
(2016).” Bryan M. Dunyak and Jason E. Gestwicki designed the experiments and 
synthetic schemes. Bryan M. Dunyak performed the experiments and chemical 
syntheses with assistance from Daniel Schwarz. 
 
4.7 Appendix 
Characterization of compounds synthesized in Chapter 4. 
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Compound 15: 
Expected MW: 926.51, Found M+ACN+: 968.93. 
 
Compound 16: 
Expected MW: 892.54, Found M+H+: 893.62. 
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Compound 18: 
Expected MW: 916.57, Found M+ACN+: 959.01. 
 
Compound 19: 
Expected MW: 860.50, Found M+H+: 861.04. 
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Compound 22: 
Expected MW: 830.53, Found M+Na+: 853.58. 
 
Compound 24: 
Expected MW: 924.42, Found M+ACN+: 966.99. 
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Compound 27: 
Expected MW: 844.51, Found M+Na+: 867.58. 
 
Compound 29: 
Expected MW: 924.42, Found M+ACN+: 966.99. 
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Chapter 5  
Conclusions and Future Directions 
 
5.1 Conclusions 
PPIases are challenging drug targets. Their active sites are shallow, hydrophobic, 
and often degenerate between family members. These complications are not 
unique to PPIases, however, as many viable protein targets exhibit “undruggable” 
features.[1] Despite these complications, the natural products FK506, rapamycin 
and cyclosporine bind PPIases with tight affinity and, in some cases, with some 
paralog specificity. Indeed, some of these PPIase natural products have even 
reached clinical approval for immune and oncology indications.[2] However, there 
have not been any approvals for small molecules that exert biological activity 
through inhibition of a PPIase. One of the major hurdles has been 
pharmacokinetics and membrane permeability. The natural products use the 
special properties of macrocycles, such as intramolecular hydrogen bonding, 
hydrophilic collapse, and cyto-specific targeting to achieve biological activity.[3-5] 
In this way, these macrocycles are able to access the important sites on the PPIase 
while maintaining intracellular partitioning. In this work, I have explored the 
characteristics underlying the mechanism of the natural product macrocycle 
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FK506 and its related derivatives to better understand how the mechanism of this 
molecule permits such a favorable pharmacological profile. 
 
In Chapter 2, I synthesized a series of bifunctional molecules that have affinity for 
FKBP and HIV protease. Inspired by the mechanism of FK506, which is naturally 
bifunctional, we hypothesized that an “FK506-like” molecule capable of 
simultaneously binding FKBP12 and HIV protease might be selectively retained in 
cells that express both targets. I gained control over the FKBP12 binding by using 
either FK506 or the weaker ligand, SLF, while affinity for HIV protease was tuned 
by installing linkers at a region that was known to impact binding. Using 
biochemical assays, I characterized the library of bi-specific molecules and 
demonstrated that they possess variable affinity for each protein target. 
 
In Chapter 3, I explored cyto-selective targeting of our bifunctional molecules. We 
hypothesized that coincident, high-level expression of both protein targets - such 
as in HIV-infected lymphocytes - would drive selective cellular targeting and 
sequestration of these compounds. In a cell-based GFP reporter assay, I 
confirmed that interactions with FKBP12 and HIV protease also control the cellular 
partitioning of these molecules. The cyto-selectivity effect was dominated by 
binding to FKBP12, likely because it represents a greater pool of available binding 
sites. Further exploring the impact of FKBP12 binding, pharmacological 
competitors and overexpression were used to systematically control the availability 
of FKBP12 for binding. Overexpression of an FKBP12 construct could enhance 
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partitioning (and anti-HIV protease activity), while binding competitors neutralized 
this effect. This concept is supported by the results of the live viral HIV-infectivity 
assays, in which FKBP12 binding determined the effectiveness of compounds. 
These results suggest that the key design principles in engineering cyto-selective 
bifunctional molecules are the abundance of the protein partners and the avidity of 
the interactions, reminiscent of what has been found for bi-specific antibodies. 
 
In Chapter 4, I wanted to see if the features outlined in Chapters 1, 2 and 3, could 
be exploited to design novel Pin1 inhibitors. The pipecolate core found in FK506 
and rapamycin provided the basis for early Pin1 inhibitors, and this scaffold 
exhibited a bound conformation highly reminiscent to that of FK506 bound to 
FKBP12. While FK506 has no measurable affinity for Pin1, we hypothesized that 
installation of an electronegative functional group could impart Pin1 binding. Thus, 
FK506 was systematically modified at the C10-hydroxyl to furnish an amine 
substituted derivative, FK-NH2. This position is in close proximity to the cationic 
groove in Pin1. Using a one-pot strategy for subsequent derivatization, we found 
that anhydrides allowed robust product formation in excellent yields (~100% in 
most cases). Direct alkylation with alkyl halides or amide formation with activated 
carboxylic acids and acyl chlorides was only moderately effective. These synthetic 
studies are expected to facilitate the creation of the next generation of potential 
Pin1 inhibitors bearing substituents designed for Pin1 binding like the sulfamic 
acid-containing compound 34. In preliminary in vitro studies, this compound had 
modest affinity for Pin1 with FKBP12 activity significantly impacted. 
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Overall, this work has contributed to our understanding of the effectiveness of 
bifunctional molecules. We found that these compounds sequester into cells at 
levels unexpected by their physicochemical properties. This effect is “tunable”, and 
mediated by the affinity and availability of the intracellular targets. In particular, we 
have demonstrated that bifunctional molecules are able to selectively partition into 
relevant cell populations, enhancing efficacy. Further, this mechanism has inspired 
the development of novel macrocyclic Pin1 inhibitors. These compounds are 
designed to address limitations in the cellular activity and usefulness of current 
Pin1 candidates. The design principles outlined here provide a framework for the 
continued development of new Pin1 inhibitors in this class. 
 
5.2 Future Directions 
5.2.1 Bifunctional molecules as a partitioning platform technology 
In this work, we demonstrated the ability of bifunctional molecules to partition 
molecules with limited permeability into relevant cells and dramatically improve 
their cellular activity. Other strategies have been commonly used for internalizing 
impermeable payloads, such as TAT-fusion proteins or octa-arginine tags,[6] 
which undergo macropinocytosis to gain entry to the intracellular space. However, 
these techniques are often complicated by limited escape from endocytotic 
vesicles in the cell[7] and/or insufficient uptake and absorption in more complex 
animal models.[8] One potential way to address these problems is with FK506 
variants. As outlined in Chapter 2, modification of the extracyclic alkene provides 
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an easily reactive handle for attachment of nearly any substrate. The favorable 
ADME properties of FKBP ligands could lead to rapid absorption and tissue 
distribution of desired cargo. Further, this attachment point on FK506 abrogates 
its immunosuppressive effects, which is a concern for FK506-based therapeutics. 
Beyond typical bioavailability of drugs, complex blood-brain barrier (BBB) 
permeability dynamics significantly limit feasible therapeutics for neurological 
conditions like neuropathic pain and neurodegenerative disease. Most BBB 
permeable molecules are very lipophilic, with both low molecular weight and polar 
surface area being a requirement, preventing the BBB penetration of many 
compounds. Surprisingly, both FK506 and rapamycin have significant BBB 
permeability despite their large size and a polar surface area two- to three-times 
the predicted cutoff.[9] Appending drugs to these macrocycles to shuttle them 
across the BBB could be a viable strategy to enhance their activity in the brain. 
 
5.2.2 Engineering bifunctional macrocycles for clinical candidates 
Co-opting the natural mechanism of the macrocyclic PPIase ligands, recent 
synthetic derivatives containing the PPIase region fused to a “variable” region have 
been heavily pursued as pre-clinical candidates (Figure 5.1).[10] This strategy 
takes advantage of two features; the FKBP partitioning effect reported in this work 
and the intracellular ternary complex formation central to the mechanism of FK506 
and related macrocycles. FKBPs have been shown to have a highly dynamic 
surface that is capable of productively interacting with other proteins to 
dramatically stabilize a ternary complex. This feature contributes to complex 
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formation mediated by FK506 and rapamycin in the FKBP12-FK506-Calcineurin 
and FKBP12-rapamycin-mTOR interactions, respectively. Attaching the FKBP 
pipecolate core to peptides targeting mutated K-RAS G12V effectively inhibits the 
RAS-RAF interaction while simultaneously binding FKBP12.[11] A similar 
approach is being developed commercially for pre-clinical testing, instead using 
the core of the bifunctional molecule Cyclosporine to inhibit RAS signaling.[12] 
Generating synthetic macrocycles built off the PPIase binding core of these natural 
products is likely to be an effective strategy at inhibiting challenging targets through 
newly formed protein-protein interactions. 
 
5.2.3 “Pinamycin” as an anti-cancer therapeutic 
In Chapter 4, we systematically explored the reactivity of the semisynthetic 
derivative FK-NH2. As mentioned, similar conversion of the tertiary hydroxyl in 
 
Figure 5.1) Artificial PPIase macrocycles that exploit the PPIase composite surface for 
inhibitory activity. FK506 is modified in the variable region through total synthesis or 
biosynthetic engineering. The highly plastic FKBP12 surface is able to cooperatively 
facilitate novel protein-protein interactions to inhibit desired targets. The variable region 
amenable for modification is shown in blue. (PDB: 1FKF, partial charges represented 
on the surface) 
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rapamycin is also effective (Figure 4.9). In part, we chose to first explore the 
reactivity of FK-NH2 because the chemical stability is greater than that of 
rapamycin. In particular, the triene region of rapamycin is highly reactive and prone 
to degradation. Thus, we characterized the FK-NH2 reactivity first so that we can 
now derivatize rapamycin under optimized conditions. Rapamycin, like Pin1, is a 
validated target in a variety of human cancers.[13, 14] Analogous to our strategy 
in Chapter 4, installation of electronegative groups at the position of the C10-
hydroxyl is designed to afford both Pin1 and mTOR inhibitory activity. In this way, 
“Pinamycin”, a novel rapamycin analog, would gain additional anti-cancer activity 
through its effects on Pin1 (Figure 5.2). In contrast, FKBP12 traditionally acts as a 
scaffold and is typically a bystander to the inhibitory effects of rapamycin on 
mTOR. Inhibiting both Pin1 and mTOR is reminiscent of cocktail therapies 
commonly used in oncology, where the effects of multiple drugs synergize to 
enhance efficacy. Additionally, mTOR and Pin1 and their respective clients are 
often over-expressed in cancer. So, as we have observed with other bifunctional 
 
Figure 5.2) Pin1 and mTOR are validated targets in numerous human cancers. A 
modified "pinamycin" derivative is expected to potently inhibit proliferation of cancer 
cells with a large therapeutic window. 
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molecules, we expect Pinamycin to possess cyto-selectivity, increasing its 
accumulation and therapeutic index in desired cell populations. 
 
5.2.4 Paralog specificity of FK-NH2 derivatives 
Finding selective molecules for individual members of the FKBP family has been 
considered a major challenge, with FK506 and other ligands being nearly 
equipotent for the majority of FKBP paralogs. Recently, Hausch et al. investigated 
a “bump-hole”[15] mutagenesis approach to engineer specificity for FKBP51 and 
FKBP52. While testing expanded derivatives of SLF (3) against mutant FKBP51 
and FKBP52, it was discovered that a subset of complementary ligands still had 
modest affinity for the wild-type FKBP51.[16] The expanded SLF derivative was 
found to induce a conformational rearrangement of the active site, with Phe-67 
rotating away from the proline pocket (Figure 5.3). This induced fit conformation 
does not appreciably occur in FKBP12 or FKBP52. A brief SAR series produced a 
compound that bound FKBP51 with single digit nanomolar potency and greater 
 
Figure 5.3) FKBP51 undergoes an expansion of the active site to tolerate high-affinity 
SLF derivatives substituted on the α-ketoamide. Phe-67 (red) rotates to allow the 
expansion and is in close proximity to the C10 modification point of FK506 and FK-NH2. 
(PDB: 3O5R and 5DIU) 
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than 10,000-fold selectivity over FKBP52 and only minimal FKBP12 binding. This 
work presents a promising therapeutic strategy for FKBP51-dependent 
pathologies. 
 
The position of modification in FK-NH2 is in close proximity to Phe-67 of FKBP51. 
Small hydrophobics here are expected to be oriented in a similar pose as the highly 
selective SLF derivatives just mentioned. The semisynthetic approaches 
discussed in Chapter 4 provide an immediate path towards testable FKBP51-
specific ligands. In parallel to our work engineering FK-NH2 derivatives to enable 
Pin1 binding, we are also exploring the ability of these molecules to gain FKBP51 
selectivity. Highly specific, cell permeable FKBP51 molecules would address a 
long-standing complication in the field of FKBP ligands with immediate 
translational potential. 
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